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Biallelic mutations in ABCC6 cause pseudoxanthoma elasticum (PXE), a disease 
characterized by calcification in the skin, eyes, and blood vessels.  While the function of 
ABCC6 and pathogenesis of PXE remains unclear, the mechanisms of related ectopic 
calcification disorders are better understood.  Generalized arterial calcification of infancy 
(GACI) is caused by biallelic mutations in ENPP1, which encodes an enzyme that 
converts ATP to AMP and pyrophosphate (PPi), a major inhibitor of tissue calcification.  
AMP is further degraded to adenosine and inorganic phosphate by CD73, encoded by 
NT5E.  We recently discovered that biallelic mutations in NT5E cause calcification of 
joints and arteries.  We reasoned that a test for genetic interaction in mouse models of 





showed fibrous capsule calcification of the vibrissae (an early marker of ectopic 
calcification) at 15 weeks of age, while Nt5e
-/-
 mice calcified after one year.  Abcc6
-/-
 
mice with one mutated Enpp1 or two defective Nt5e alleles showed accentuated 
calcification with strong statistical evidence for synergy.  Additionally, ABCC6, ENPP1, 
and CD73 exhibited regulatory interactions; human fibroblasts with biallelic ABCC6 
mutations had increased ENPP1 and decreased CD73 activity.  Taken together, these data 
suggest that ABCC6 participates with ENPP1 and CD73 in ATP metabolism.  Under 
osteogenic culture conditions, ABCC6 mutant cells calcified, suggesting a provoked cell-
autonomous defect.  Using a conditional Abcc6 knockout mouse model, we excluded the 
prevailing hypothesis that singularly invokes failure of hepatic secretion of an endocrine 
inhibitor of calcification.  Instead, deficiency of Abcc6 in both local and distant cells was 
necessary to achieve the early onset and penetrant ectopic calcification observed upon 
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constitutive gene targeting.  Given their ability to recapitulate pathogenic events, PXE 
patient fibroblasts emerged as a viable model for investigating therapies.  ABCC6 mutant 
cells additionally had increased expression and activity of tissue non-specific alkaline 
phosphatase (TNAP), an enzyme that degrades PPi, a major inhibitor of calcification.  A 
novel, selective, and orally bioavailable TNAP inhibitor prevented calcification in 
ABCC6
 
mutant cells in vitro and attenuated both the development and progression of 
calcification in Abcc6
-/-
 mice in vivo, without the deleterious effects on bone associated 
with other proposed treatment strategies.  In summary, our studies provide evidence that 
ectopic calcification in PXE integrates both local and systemic perturbations of 
extracellular ATP metabolism, which can be attenuated in patient cells or Abcc6 
knockout mice with a TNAP inhibitor. 
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Once considered passive precipitation of calcium and phosphate (Pi), ectopic 
calcification is now seen as a complex process actively regulated by several circulating 
and local factors.  These factors maintain vessel and tissue homeostasis, which normally 
involves trophic inhibition of calcification and is disrupted in pathological disorders.  
Several rare Mendelian diseases, as well as some common disorders, present with 
strikingly similar histological findings but vastly different clinical manifestations and 
pathologic sequelae.  Here, we describe the clinical presentations, diagnostics, molecular 
genetics, and treatment of the known disorders of ectopic calcification, in addition to 
reviewing experimental models and disease mechanisms. 
  
II. DISORDERS OF ECTOPIC CALCIFICATION   
Generalized Arterial Calcification of Infancy (GACI) 
Clinical Presentation and Diagnostic Aspects 
Infantile calcification of the arteries was first described by Durante in 1899
1
, and the first 
report in the English medical literature dates back to 1901
2
.  Since then, it has been 
known by various different names, including idiopathic obliterative arteriopathy, infantile 
calcifying arteriopathy, occlusive infantile arteriopathy, medial coronary sclerosis of 
infancy, diffuse arterial calcifying elastopathy of infancy, arteriopathia calcificans 
infantum, and perhaps more commonly as Idiopathic Infantile Arterial Calcification 
(IIAC)
3
.  Since the identification of the molecular etiology in 2003
4
, the preferred 
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nomenclature has been GACI.  The incidence of GACI, calculated from the carrier 
frequency noted in a cohort of over 60,000 exomes from unrelated adults, should be 
approximately 1 in 200,000 live births, although it is likely that only a fraction of affected 
infants receive that diagnosis.  GACI shows a bimodal age of onset, with about half of all 
patients presenting in utero or during the first week of life, and the other half presenting 
later in life, with a median age of onset of three months
5
.  Common signs of the disease in 
utero include fetal distress, polyhydramnios, and effusions or hydrops, while a common 




GACI is characterized by diffuse calcification of large- and medium-sized arteries (Fig. 
1A).  Extravascular calcifications can occur around the joints (Fig. 1B) in 29% of cases
6
, 




, pancreas, liver, and kidneys
8,13
.  Skin and 
retinal findings typical of pseudoxanthoma elasticum (PXE; see below) can also present 
later in life in individuals who survive infancy
8,13–16
.  Elevated inflammatory markers 
such as white blood cell count and C-reactive protein commonly occur, leading to the 
erroneous diagnosis of sepsis.  Despite the best medical care, the mortality rate remains 




GACI is diagnosed through imaging studies, including ultrasonography, and 
echocardiography that detect vessel echobrightness, as well as computed tomography 
(CT), which remains the preferred technique to evaluate vascular calcification.  In the 
past, the diagnosis was made by histologic means, either through the biopsy of a medium-




Fig. 1.  Common clinical and histological features of GACI.  (A) Ultrasound imaging 
showing luminal narrowing and echobrightness (arrow) of the distal aorta in a child.  (B) 
Calcification noted in the right ankle joint (arrow).  (C) Medium-sized vessel within 
connective tissue showing calcification of the internal elastic lamina (hematoxylin and 
eosin stain).  (D) Bilateral genu valga in a child with untreated hypophosphatemic rickets 
due to ENPP1-associated GACI. 
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calcification of the internal elastic lamina of large- and medium-sized arteries (Fig. 1C); 
fibrointimal hyperplasia frequently contributes to luminal narrowing and can occur in the 
absence of calcification.  The authors know of one child with biallelic ENPP1 mutations 
(see Molecular Genetics below) with no arterial calcifications on CT imaging, but with 
diffuse arterial narrowing, initially diagnosed as fibromuscular dysplasia.  
 
Molecular Genetics  
GACI generally results from biallelic mutations in ENPP1, which encodes an 
extracellular ectonucleotide pyrophosphatase that converts ATP into AMP and 
pyrophosphate (PPi)
4
.  While mutations in ENPP1 account for 67% of all cases of GACI, 
biallelic mutations in ABCC6 account for 9% of cases
8
, and over 20% of all patients have 
no known molecular etiology.  In general, the different molecular bases of GACI are 
clinically indistinguishable.  However, hypophosphatemic rickets develops in the 
majority, if not all, survivors of GACI carrying ENPP1 mutations
6
 (Fig. 1D), while it is 
not a complication of GACI due to ABCC6 mutations (see below).  Hearing loss, either 
conductive, sensorineural, or mixed, can also complicate ENPP1-GACI at any point in a 
patient’s lifetime, including the neonatal period
9
.  No genotype-phenotype correlation is 
known for patients with ENPP1-GACI, other than all patients homozygous for the 





Because of the lack of understanding of the disease pathogenesis, treatment options for 
disorders of ectopic calcification have been limited.  One possible therapy consists of 
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bisphosphonates, which have a pyrophosphate (PPi) backbone that inhibits mineral 
formation, and a side chain that inhibits mineral resorption.  Although the main reason for 
using bisphosphonates in other conditions, such as osteoporosis, stems from their 
antiresorbtive effect, the rationale for their use in GACI is related to their 
antimineralization effect.  First-generation bisphosphonates, specifically etidronate, have 
been proposed as treatment for vascular calcification disorders
17
, and are currently being 
used to treat GACI.  Because of the limited number of GACI patients, the therapeutic 
efficacy has not been well-established, though a retrospective study has shown that 
etidronate treatment was associated with better clinical outcomes and prolonged 
survival
6
.  The optimal duration of treatment remains to be established, but prolonged 
bisphosphonate therapy can lead to severe skeletal toxicity
18
.  Treatment of subsequent 
rickets, when performed judiciously, does not lead to worsening of vascular 
calcification
19





Arterial Calcification due to Deficiency of CD73 (ACDC) 
Clinical Presentation and Diagnostic Aspects 
In 2011, mutations in NT5E were identified in members of three families with 
symptomatic arterial and joint calcification
20
.  Today, a total of 13 patients are followed 
at the National Institutes of Health, and more patients have been identified around the 
world
21–23
.  Patients typically present in their late teenage years or early adulthood with 
joint pain, mostly in the hands and feet, but a rheumatology evaluation fails to provide a 
specific diagnosis despite radiographs showing periarticular calcification
21,24
.  Patients 
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later develop claudication, and plain radiographs show massive calcification of the 
arteries of the lower extremities (Fig. 2). Patients lack classical risk factors for 
cardiovascular disease, such as diabetes or renal insufficiency, but are treated empirically 
for peripheral vascular disease, either medically or surgically. Isolated patients with 
ACDC have had calcification of upper extremity vessels
22
, splenic artery, coronary 
arteries, soft tissue in the neck, and a calcified brain meningioma. 
 
Molecular Genetics 
ACDC results from biallelic mutations in NT5E, which encodes CD73, an ecto-5’-
nucleotidase that degrades AMP to adenosine and inorganic phosphate (Pi)
20
.  Mutations 
identified in the original three families caused reduced endoplasmic reticulum retention 
and reduced trafficking of the defective protein to the plasma membrane
25
. No genotype-
phenotype correlation is known. 
 
Treatment 
A phase 1 clinical trial to evaluate the effectiveness of etidronate is currently underway 
(ClinicalTrials.gov identifier: NCT01585402). 
 
Pseudoxanthoma elasticum (PXE) 
Clinical Presentation and Diagnostic Aspects 
PXE is characterized by fragmentation and mineralization of elastic fibers, mainly 
affecting the skin, retina, and cardiovascular system.  In 1881
26




















skin findings and attributed them to a form of diffuse xanthelasma.  Later, Ferdinand-
Jean Darier realized that the skin lesions were not xanthomatous, but rather caused by 
calcification of the elastic fibers; thus, he coined the term pseudoxanthoma elasticum
27
.  
In 1929, the association of the typical skin findings with retinal angioid streaks was 
independently reported by two Swedish doctors, Ester Grönblad
28
 and James 
Strandberg
29
; the disorder is still sometimes known as Grönblad-Strandberg syndrome.   
 
Although it was initially thought to be an exceedingly rare disease, with older literature 
mentioning a prevalence of 1 in 1,000,000, a prevalence as high as 1 in 25,000 has been 
proposed
30
.  Based on the allele frequency for the most common ABCC6 mutation, 
R1114*, a prevalence as high as 1 in 4,450 has been calculated in the Dutch 
population
30,31
.  A founder effect has been reported in the Afrikaner population of South 
Africa
32




From a series of 100 patients, the mean age at onset of symptoms was 13.5 years, with 
mean age at diagnosis of 22.9 years
33
.  The first symptoms are almost always 
cutaneous
33
, in the form of small, asymptomatic, yellow papules that coalesce over time 
into larger plaques.  The appearance of the skin has been described as that of “plucked 
chicken”, “Moroccan leather”, “cobblestone”, “crépe-like”, or “pseudoxanthomatous”
34
.  
In more advanced stages, the papules can become obscured by folds of redundant skin
34
.  
The first site of involvement in 96% of cases is the lateral neck, but the axillae, 
antecubital fossae, inguinal fossae, and groins can be involved, typically following a 
cephalad to caudal order of progression
33
.  Other affected areas include the inner aspect 
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of the lower lip (33% of cases), rectal mucosae, supraumbilical area, flexor surface of the 
wrist, medial thighs, dorsum of the ankles, penis, and genital labia.
33
  In cases with facial 
involvement, the skin redundancy leads to a “hound dog” appearance. 
 
The typical retinal findings of PXE include angioid streaks, mottled hyperpigmentation 
(peau d’orange), atypical drusen, and retinal hemorrhages (Fig. 3).  Angioid streaks are 
irregular lines that radiate from the optic disc, and are the manifestation of ruptures in 
Bruch’s membrane; they are seen in 83% of cases and start appearing during the second 
decade of life
33
.  Peau d’orange represents a mottled pigmentation of the retinal pigment 
epithelium best seen in the periphery of the retina; this finding is present in 96% of 
patients, making it the most common retinal sign of PXE
33
.  Other findings include 
atypical drusen (52% of cases) and hyperpigmented spots on both sides of an angioid 
streak (“owl’s eyes”)
33
.  All these findings are asymptomatic until neovascularization 
occurs, leading to hemorrhages and the consequent visual loss. 
 
Regarding cardiovascular complications, intermittent claudication is present in 30% of 
cases, angina pectoris in 13%, gastrointestinal bleeding in 8%, mitral valve prolapse in 




Testicular microlithiasis affects the majority of male patients with PXE
35
, sometimes very 
early in life
36








Fig. 3.  Fundus photograph of a patient with PXE.  Oval indicates peau d’orange in 
the peripheral retina, arrow indicates macular hemorrhage, and arrowheads point to 










The minimal criteria for establishing a clinical diagnosis of PXE requires the presence of 
angioid streaks in the retina in addition to typical skin findings with characteristic 
histopathologic changes of mineralization and fragmentation of elastic fibers 
(elastorrhexis)
38
.  The first finding is that of mineralization of the central core of the 
elastic fiber, followed by formation of central holes, and then fragmentation of the 
fibers
39
.  Special stains used in light microscopy include Verhoeff-van Gieson (staining 
elastic fibers black) and calcium stains such as von Kossa and alizarin red (staining 
calcium brown black and reddish orange, respectively).  
 
There are several conditions that can cause PXE-like phenotypes.  The reported incidence 





the latter in patients over 40 years old.  Angioid streaks have been found in 20% of 
patients with β-thalassemia
42
 (showing a positive correlation with age) and in 10% of 
patients with sickle-thalassemia
43
.  Of 40 patients with β-thalassemia, 55% had 
calcification of the posterior tibial arteries, 20% had skin lesions typical of PXE, and 52% 
had angioid streaks, with 85% having at least one of the three
44
.  The pathology of the 
skin lesions, based on light microscopy, electron microscopy, and 
immunohistochemistry, is identical to that seen in PXE
45
.  Exposure to potassium nitrate 
(saltpeter) is also associated with skin lesions that are clinically and histopathologically 
identical to those of PXE
46,47
.  Penicillamine use can induce similar skin changes, 
described as pseudo-pseudoxanthoma elasticum
48–50
; there is a case of familial pseudo-
PXE in relatives who were taking penicillamine for the treatment of cystinuria
51
.  PXE 
has also been described in three liver transplant recipients, although liver specimens from 
12 
 
donors did not reveal mutations in ABCC6
52
.  Patients with juvenile Paget disease can 
also have PXE-like skin lesions
53–56
 and retinal findings
57–59
.  Finally, an unknown 
disorder with manifestations of pseudoxanthoma elasticum, hyperphosphatemia, 





PXE is most commonly caused by mutations in ABCC6, but it can also be caused by 
mutations in ENPP1
8,61
.  No genotype-phenotype correlation is known
62
, other than 
patients with ENPP1-associated PXE are likely to have experienced rickets during 
childhood or adolescence.  PXE is inherited in an autosomal recessive manner; although 
historically there have been many reports of autosomal dominant inheritance, cases with 
unambiguous PXE in two different generations have been proven to represent instances 
of pseudominance
63,64
.  Polymorphisms in the xylosyltransferase genes have been 
described as modifiers of PXE phenotype severity
65
.  PXE-like disorder with multiple 
coagulation factor deficiency (OMIM 610842) is an autosomal recessive condition due to 
mutations in the GGCX gene.  Similarities to PXE include yellowish papules, retinal 
angioid streaks and peau d’orange, and dermal elastorrhexis
66
.  Differences from PXE 
include more diffuse skin involvement with cutis laxa over time, no decrease in visual 
acuity, the presence of coagulation abnormalities, and the finding of mineralization of the 







No specific treatment exists.  Therapeutic options for choroidal neovascularization 
include laser photocoagulation, transpupillary thermotherapy, photodynamic therapy, and 





Familial chondrocalcinosis type 2 
Clinical Presentation and Diagnostic Aspects 
Familial chondrocalcinosis was first described by Zitnan and Sitaj in 1957
68
, during the 
Ninth International Congress on Rheumatic Diseases in Toronto.  It is characterized by 
early-onset deposition of calcium pyrophosphate dihydrate (CPPD) in cartilage, mainly 
affecting the knees and wrists (hyaline cartilage), and the menisci, pubic symphysis, and 
intervertebral disks (fibrocartilage)
69
.  This crystal deposition is evidenced 
radiographically, and leads to arthropathy.  The clinical patterns described include 
pseudogout alone (with acute or subacute attacks, 19%), pseudogout with osteoarthritis 
(chronic osteoarthritis with superimposed attacks, 44%), pseudo-osteoarthritis alone 
(similar to osteoarthritis but with a different pattern of joint involvement affecting the 
metacarpophalangeal joints, wrists, elbows, and shoulders in a symmetric fashion, 22%) 
and pseudo-rheumatoid arthritis (chronic inflammatory arthritis, 15%)
69
.  Pseudogout 
attacks typically start between the late third and early fourth decades
70
.  There is 
radiographic evidence of chondrocalcinosis affecting the knees (93%), pubis symphisis 
(67%), wrists (59%), and hips (52%)
69
.  Occasionally, affected individuals can show 
radiographic evidence of chondrocalcinosis and still remain asymptomatic, while others 
can have destructive arthropathy necessitating joint replacement
69
.  Laboratory studies do 
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not disclose blood abnormalities of mineral metabolism
69
.  CPPD crystals can be 
identified in synovial fluid by their positive birefringency on compensated polarized light 
microscopy.  
 
Other genetic disorders that have been associated with CPPD deposition include 
hemochromatosis
71












Familial chondrocalcinosis type 2 results from mutations in ANKH
80
, which also causes a 
rare skeletal dysplasia known as craniometaphyseal dysplasia and characterized by 
hyperostosis, sclerosis of craniofacial bones, and abnormal modeling of the metaphyses 
of long bones
81
.  Both conditions are inherited in an autosomal dominant manner, with 
chondrocalcinosis likely being caused by gain-of-function mutations, and 
craniometaphyseal dysplasia by dominant negative mutations
82
.  Mutations that lead to 
craniometaphyseal dysplasia cluster in the C-terminus of ANKH, whereas mutations in 
the N-terminus result in chondrocalcinosis
83
.  Craniometaphyseal dysplasia has been 
reported to cosegregrate with chondrocalcinosis in females from an Australian family
84
.  
An autosomal recessive disorder caused by homozygous mutations in ANKH was 
reported in one family, whose affected members presented with painful periarticular 
calcification of small joints, progressive spondyloarthropathy leading to ankylosis, 







There is no specific therapy for the condition.  Treatment is symptomatic, including the 
use of nonsteroidal anti-inflammatory drugs and intra-articular or systemic 
glucocorticoids for the management of pain or inflammation. 
 
Familial Tumoral Calcinosis (FTC) 
Clinical Presentation and Diagnostic Aspects 
FTC is characterized by the development of calcified masses around one or more large 
joints (Fig. 4).  It was first described by Giard and Duret in 1898 and 1899, 
respectively
86,87
.  Teutschlaender called the disease lipocalcinogranulomatosis and 
studied it since the 1930s in Europe
88
, where the condition came to be called 
Teutschlaender disease.  Inclan was the first to report the disease in the American 
literature, and he coined the term tumoral calcinosis
89
, which subsequently became 
widely adopted. FTC can be either hyperphosphatemic or normophosphatemic.  
 
A condition known as hyperostosis-hyperphosphatemia syndrome is characterized by 
cortical hyperostosis, periosteal reaction, and  hyperphosphatemia, and is now known to 
belong to the spectrum of hyperphosphatemic FTC
90,91
.  A review of 56 patients with 
molecularly-confirmed hyperphosphatemic FTC found hyperphosphatemic FTC alone in 
54% of cases, hyperostosis-hyperphosphatemia alone in 11%, and combined 
hyperphosphatemic FTC with hyperostosis in 36% of patients
92
.  Males and females are 
equally affected, but hyperostosis occurs more commonly in females
92
.  Age at 
presentation was 2 to 13 years in 78% of cases
92





, and included short bulbous teeth with blunted roots, thistle-shaped dental pulps, 
obliteration of the pulp chamber and root canal, and pulp stones
93
.  Vascular calcification 
was present in 18%, and eye involvement in 16% of patients
92
, including calcification of 
the eyelids or conjunctiva, band keratophy, retinal angioid streaks, or optic nerve head 
drusen
92,94,95




The laboratory findings of hyperphosphatemic FTC include increased tubular resorption 
of Pi for the degree of hyperphosphatemia, elevated or inappropriately normal 1,25-
dihydroxyvitamin D, low intact FGF23 with markedly increased C-terminal FGF23–
indicative of increased FGF23 cleavage–with normal calcium and parathyroid hormone.  




Normophosphatemic FTC is characterized by the appearance of an erythematous papular 
eruption during the first year of life (earlier than the typical age of onset of 
hyperphosphatemic FTC), followed by the appearance of calcified masses in the 





Patients and families with hyperphosphatemic FTC have mutations of either the 
fibroblast growth factor 23 (FGF23), polypeptide N-acetylgalactosaminyltransferase 3 
(GALNT3), or Klotho (KL) genes, all of which encode proteins involved in Pi regulation.  
FGF23 is a secreted osteocyte protein, whose post-translation processing requires 




Fig. 4.  Patient with familial tumoral calcinosis.  Evidence of an amorphous, 
multilobulated calcific mass around the right hip joint (Courtesy of Drs. Rachel I. Gafni, 












membrane protein complex comprising the FGF receptor and co-receptor, Klotho, to 
promote renal Pi excretion by downregulating type 2 sodium-phosphate co-transporters.   
 
FGF23 also decreases intestinal Pi absorption by inhibiting the renal via D-1alpha-
hydroxylase mediated synthesis of 1,24-dihydroxyvitamin D.  Mutations in GALNT3 
account for 75% of FTC cases, while mutations in FGF23 and KL account for 23% and 
2%, respectively.  Vascular calcification is more common in patients carrying FGF23 




Normophosphatemic FTC is caused by biallelic loss-of-function mutations in SAMD9, 
while the newly-described MIRAGE syndrome (Myelodysplasia, Infection, Restriction of 
growth, Adrenal hypoplasia, Genital phenotypes, and Enteropathy) is caused by de novo 




Regardless of the gene involved, all forms of FTC show autosomal recessive inheritance. 
 
Treatment 
Treatment is targeted at decreasing enteral absorption of Pi or increasing the renal 
excretion of Pi.  Decreased intestinal absorption can be achieved by dietary phosphate 
restriction (with a goal of 400 to 900 mg/day) and use of Pi binders, such as aluminum 
hydroxide or sevelamer. Increased renal excretion can be achieved by the use of 
acetazolamide or probenecid
93,97,100
.  The response to treatment is quite variable, with 
some patients showing complete resolution of lesions, and others showing no 
19 
 
improvement.  In patients with systemic inflammation, the use of interleukin-1 
antagonists can be beneficial
97
.  Surgical debulking can be performed in case of pain, 
deformity or restriction of joint mobility, but lesions tend to recur. 
 
Idiopathic Basal Ganglia Calcification (IBGC) 
Clinical Presentation and Diagnostic Aspects 
Vascular calcification of the basal ganglia was first described by Delacour in 1850
101
, in a 
56-year-old man with weakness and spasticity of the lower extremities, as well as 
tremor
102
.  Eighty years later, Karl Theodor Fahr reported the case of an 81-year-old man 
with a long history of dementia; that was a sporadic rather than a familial case.  The 
patient may have had hypoparathyroidism, and the calcification was primarily located in 
the white matter vasculature, not in the basal ganglia.  This, added to the fact that over 
time the term Fahr disease came to be used for any form of bilateral basal ganglia 





In IBGC, calcifications are found not only in the basal ganglia (Fig. 5), but also in the 
thalamus, dentate nucleus, and centrum semiovale
104
. In a review of 99 cases, 67 were 
symptomatic at the time of evaluation
104
. The most common symptoms were movement 
disorders (55%), cognitive defects (39%), speech disorder (36%), cerebellar signs (36%), 
psychiatric manifestations (31%), pyramidal signs (22%), sensory symptoms (16%), 




Fig 5.  Brain computed tomography of a patient with IBGC showing bilateral 











the movement disorders, the most common were parkinsonism (57%), followed by 
chorea (19%), tremor (8%), dystonia (8%), athetosis (5%), and orofacial dyskinesia 
(3%)
104
.  The mean age of onset of symptoms is 39 ± 20 years
105
; 25% have onset before 
18 years of age, presenting predominantly with isolated psychiatric or cognitive signs, 
and 25% have onset after 53 years of age, presenting mainly with movement disorders
106
.  





































 and Nasu-Hakola syndrome
121
.  Lipoid proteinosis is typically 
associated with calcification of the amygdalae, but sometimes the calcium deposits can 





There are currently four genes that are known to account for the IBGC phenotype: 
SLC20A2, PDGFB, PDGFRB, and XPR1, all exhibiting autosomal dominant inheritance. 
Approximately 41-50% of familial cases were initially reported to be caused by 
heterozygous mutations in SLC20A2
123,124
, with 4.3% of sporadic cases caused by 
mutations in that gene
123
.  However, a recent French series described SLC20A2 mutations 
in 20% of familial IBGC and 17.2% of sporadic cases, PDGFB mutations in 10% of 
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familial and 13.8% of sporadic cases, and PDGFRB mutations in 5% of familial and 
6.9% of sporadic cases
125
.  Mutations in XPR1 account for less than 8% of patients who 
are negative for those three genes
126
.  Calcification tends to be more severe in patients 





No specific treatment exists for IBGC.  Treatment is targeted to the symptoms, including 
medications for movement disorders, psychiatric symptoms, seizures and migraines.  
Etidronate use was attempted in one patient, leading to improved speech and gait, but 
there was no improvement in spasticity, dystonia, or ataxia, and no reduction in 
intracranial calcification
127
.  Alendronate was recently used in seven patients, with good 
tolerance and either stability or subjective improvement of symptoms, particularly in 
younger patients
128




Clinical Presentation and Diagnostic Aspects 
Keutel et al. first described this condition in 1972 in a brother and sister born from a 
consanguineous union
129
.  The disease is characterized by diffuse cartilage calcification, 
including the nose, pinna, larynx, trachea, bronchi, and costochondral junctions
129
, which 
can lead to persistent respiratory symptoms (68%), recurrent sinusitis and otitis media 
(67%), and tracheobronchial stenosis (50%)
130
.  Patients also have stippled epiphyses of 





, the latter typically mixed.  Midface hypoplasia with a flat nasal bridge 
confers a classic facial appearance known as Binder phenotype
131
.  Brachytelephalangy, 
with shortening and broadening of the first through fourth distal phalanges and sparing of 
the fifth finger, is considered highly specific for Keutel syndrome, and is present in 75% 
of patients
132
.  Autopsy of the original brother described by Keutel revealed calcification 
of the internal elastic lamina of the pulmonary, coronary, hepatic, renal, meningeal, and 
cerebral arteries
133
.  Long term follow up of patients into adulthood identified multiple 
erythematous macular skin lesions located in the trunk, neck, dorsum of hands and 
elbows, typically appearing after the age of 30 years old
134
.  Adult patients can also 





The main differential diagnosis is that of brachytelephalangic chondrodysplasia punctata 
(CDPX1) due to arylsulfatase E deficiency, as this condition can also be accompanied by 
the Binder phenotype, epiphyseal stippling, tracheal calcification and 
brachytelephalangy
135
; although the latter tends to affect all digits
132
, sparing of the fifth 
distal phalanx has also been described in CDPX1
135
. Another close differential diagnosis 
is pseudo-warfarin embryopathy due to vitamin K epoxide reductase deficiency, since 
patients with this syndrome also have digital hypoplasia, nasal hypoplasia, and stippled 
epiphyses; those patients, however, also have coagulation abnormalities
136
.  Other genetic 










Keutel syndrome is an autosomal recessive condition caused by mutations in matrix Gla 
protein, encoded by MGP
139
.  The glutamate residues of matrix Gla protein are converted 
to γ-carboxyglutamate by the action of GGCX, with vitamin K as a cofactor for the 
reaction.  Decreased levels of carboxylated matrix Gla protein have been reported in a 
patient
140
.  No genotype-phenotype correlation is known to date. 
  
Treatment 
No specific treatment is available.  In particular, vitamin K supplements failed to increase 




Singleton-Merten syndrome (SMS) 
Clinical Presentation and Diagnostic Aspects 
In 1973, Edward Singleton and David Merten first described the condition that now 
carries their name.  This disorder is characterized by aortic and valvular calcification 
(10/11, 91%; Fig. 6A), cardiac arrhythmia (6/11, 55%; Figure 6A), subungual 
calcification (3/8, 38%), acro-osteolysis (6/9, 67%; Fig. 6B), short stature (6/9, 67%), 
osteopenia (9/10, 90%; Fig. 6A), scoliosis (3/10, 30%), wide medullary cavities of the 
phalanges (9/10, 90%), spontaneous tendon rupture (6/11, 55%), joint subluxation (8/9, 












Fig. 6.  Typical clinical manifestations associated with Singleton-Merten syndrome.  
(A) A pacemaker generator is noted (oval), implanted due to the presence of 
bradyarrhythmia; the aorta is markedly calcified (“porcelain aorta”, arrowheads); the 
vertebral bodies show evidence of low bone mineral density (arrow). In addition, 
sternotomy wires can be seen, reflecting prior open heart surgery for mitral valve 













 account for this 
autosomal dominant condition.  Mutations in either gene lead to interferon signature 
upregulation.  Both genes encode components of the RIG-I-like Receptor (RLR) 
pathway, involved in antiviral innate immunity.  A third component of this pathway is 
encoded by DHX58, not yet associated with a human disease.  The authors have 
evaluated a family with Singleton-Merten syndrome without mutations in the two known 
genes, so mutations in other genes, particularly those participating in the RLR pathway, 
could lead to SMS.  Regarding genotype-phenotype correlation, dental involvement has 





No specific treatment is known, but medications that modulate interferon pathway 
activation might be beneficial.    
 
Mönckeberg medical calcific sclerosis 
Mönckeberg medial calcific sclerosis is characterized by calcific deposits in the small and 
medium-sized muscular arteries that occurs independently of inflammation or 
atherosclerosis.  Since the intima is not involved, luminal narrowing does not occur.  It 
was originally described by Johann Georg Mönckeberg in 1903.  This type of 
calcification is typically associated with chronic kidney disease, diabetes, aging, 
osteoporosis, and vitamin D toxicity.  Although historically considered an incidental 
finding without clinical repercussions, it has more recently been described as a risk factor 
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for cardiovascular disease.  Upon histopathological review of cases of Mönckeberg 
sclerosis, all had calcification of the internal elastic lamina, while calcification of the 
media was frequent but not universal. Thus, among the different causes of acquired 
vascular calcification, Mönckeberg’s sclerosis most closely mimics the pattern of 
involvement seen in hereditary causes of vascular calcification. 
 
III. ANIMAL MODELS 
Animal models of ectopic calcification can produce critical insights into disease 
mechanism, uncover novel therapeutic targets, and provide evidence for preclinical drug 
efficacy.  Here, we describe the rodent models that have been generated to recapitulate 
human diseases of pathological ectopic calcification. 
 
GACI, PXE, and ACDC  
The first sign of calcification in GACI, PXE, and ACDC mouse models occurs in the 
fibrous capsule surrounding their vibrissae (whiskers) on their snout.  While there is no 
human equivalent for this fibrous structure, it has been well-established as an early 
biomarker for ectopic calcification.  Mice harboring biallelic loss-of-function mutations 
in Enpp1 manifest robust vibrissae capsule calcification by one month of age and variable 
aortic and kidney calcification by five months of age.  Enpp1 mutant mice also develop 
debilitating extraarticular joint capsule calcification and ankylosis in their forelimbs and 
vertebral column, leading to progressively limited mobility and death, typically within six 
to eight months.  The architecture and mineralization of the long bones are disrupted in 
Enpp1 mutant mice, emphasizing the importance of ENPP1 in both bone and vessel 
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homeostasis.  Specifically, Enpp1 mutant mice have reduced trabecular mass and cortical 
bone thickness with hypomineralization in the femur and tibia.  The bone phenotype in 
Enpp1 mutant mice has been attributed to increased plasma FGF23 levels, and 
consequently decreased circulating calcium and Pi
144
, though the mechanism by which 
Enpp1 mutations lead to excessive FGF23 production remains unknown. 
 
Like Enpp1 mutant mice, Abcc6 knockout mice develop ectopic fibrous capsule vibrissae 
calcification, but with a milder and more delayed presentation.  When aged beyond one 
year, Abcc6 knockout mice develop focal and sporadic calcification in the skin, eyes, 
vessels, and other solid organs, recapitulating the common adult-onset and often indolent 
course of human PXE
145
.  Nt5e knockout mice develop minor vibrissae capsule 
calcification at approximately one year of age without evidence of other ectopic 
calcification.   
 
Though the phenotype of fibrous capsule vibrissae calcification has variable onset and 
severity, the observation that it is shared among Enpp1, Abcc6, and Nt5e mutant mice 
indicates the potential for a unifying disease mechanism.  Nevertheless, genotypic 
heterogeneity cannot be excluded.  While it is already established that ENPP1 and CD73 
work in the same metabolic pathway, ENPP1 breaking down ATP to AMP, the substrate 
for CD73, the role of ABCC6 remains unknown.  These data suggest that ABCC6 is also 




Use of an acceleration diet composed of high Pi and low magnesium or warfarin and 
vitamin K1 stimulates the Enpp1 and Abcc6 mutant mouse models to develop multi-
organ pathological calcification within one to six months
146,147
.  Whereas wildtype mice 
do not typically calcify when placed on an acceleration diet, mice harboring biallelic 
Enpp1 or Abcc6 mutations exhibit robust aberrant vascular and solid organ 
calcification
146–148
.  Nt5e knockout mice develop extraarticular joint capsule calcification 
at approximately one year of age when provoked with an acceleration diet
149
.   
 
Since diet modification exacerbates disease presentation in the mice, manipulation of the 
dietary mineral content has also been attempted to attenuate disease progression, 
specifically in Abcc6 knockout mice.  While variation in dietary calcium or Pi does not 
affect calcification in this mouse model, increasing magnesium reduces vessel 
calcification in the heart and kidney at one year of age
150
 and prevents new, but does not 
reverse existing, calcium Pi deposition
151,152
.  The mechanism by which high magnesium 
modulates the calcification process in vivo remains unclear, although it has been shown 
that magnesium can physically disrupt the crystal lattice, slowing hydroxyapatite 
formation
153
.  Importantly, magnesium and other serum minerals including Pi, sodium, 
calcium, and chloride, are normal in Abcc6 mutant mice
154
 indicating that magnesium is 
likely modifying disease presentation through a parallel pathway instead of correcting a 
basic defect in the disease.   
 
In addition to high dose magnesium, nonhydrolyzable analogs of PPi, such as 





.  First-generation bisphosphonates, specifically etidronate, have been 
proposed as treatments for vascular calcification disorders
17
.  A recent study reported that 
treating Enpp1 mutant mice with etidronate (100 µg/kg intraperitoneally) twice a week 
did not resolve the calcification phenotype
156
.  However, high-dose oral etidronate (240 
mg/kg/day) was effective at attenuating fibrous capsule vibrissae calcification in Abcc6 
mutant mice
157
.  The etidronate dose used in the latter mouse trial was 12 times higher 
than the corresponding dose used to treat osteoporosis in humans, and it resulted in 
significant changes to bone microarchitecture
157
.   
 
While treatment strategies have focused on disrupting calcium Pi precipitation, correction 
of the basic defect has also been pursued.  An enzyme replacement strategy with 
recombinant ENPP1-Fc fusion protein restored circulating serum PPi levels and 
prevented mortality and vascular calcification in the aorta, heart, and coronary arteries in 
Enpp1 mutant mice fed an acceleration diet
158
.  When ENPP1-Fc treatment was 
discontinued, pathologic vascular calcification slowly reemerged but did not lead to 
death, suggesting that early intervention during a critical interval can extend survival.  
The efficacy of ENPP1-Fc enzyme replacement in other disorders with defects in 
extracellular ATP metabolism or more common disorders with established deficiencies in 
PPi remains to be determined. 
 
Overexpressing Alpl, the gene that encodes tissue non-specific alkaline phosphatase 
(TNAP), in vascular smooth muscle cells has also been used as a model to recapitulate 
the GACI phenotype and provide insight into a novel therapeutic target.  Among other 
31 
 
things, TNAP degrades PPi, the main negative regulator of calcification, and is increased 
in cell lines derived from GACI, PXE, and ACDC patients
20,45
.  TNAP-overexpressing 
mice have extensive aortic calcification, high blood pressure, cardiac hypertrophy, and 
increased mortality
160
.  This mouse model has been treated with the pharmacological 
small molecule TNAP inhibitor SBI-425 to suppress the genetically induced, high TNAP 
levels and successfully prevent the pathologic calcification
160
.  Genetic manipulation to 
knockout TNAP in Enpp1 mutant mice also ameliorates the calcification phenotype, 
specifically the intervertebral mineral deposits
161
, further establishing TNAP as a 
drugable target in an endogenous disease model.  Use of TNAP inhibitors in other mouse 
models in which elevated TNAP has been noted in patients’ cells are currently underway. 
 
Chondrocalcinosis and craniometaphyseal dysplasia 
As in humans, mice with mutations in Ank, which encodes a transmembrane PPi 
transporter, manifest variable phenotypes with the unifying trait of ectopic calcification.  
Mice with complete Ank deficiency develop extraarticular joint capsule calcification and 
progressive ankylosis of the vertebral column, leading to progressive joint immobility 
and complete rigidity and death by six months of age
162–164
.  Mice with joint-specific 
knockout of Ank have a delayed onset, but eventually develop the same characteristic 
phenotype as the complete Ank knockout mice demonstrating that, although Ank is 




While the ectopic calcification in Ank-deficient mice is composed of hydroxyapatite 
crystals, the crystals found in humans with chondrocalcinosis consist of CPPD.  This 
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fundamental difference in pathology is a consequence of the underlying genetic 
mutations; while Ank deficiency in mice results in loss of function of the transporter and 
decreased extracellular PPi, human chondrocalcinosis mutations are likely gain-of-
function and lead to an accumulation of extracellular PPi
164
.  These conclusions are 
supported by data showing that human disease-causing chondrocalcinosis mutations 
retain normal transport activity of PPi in Xenopus oocytes and can partially rescue the 




In recent studies, closer examination revealed that Ank complete knockout mice exhibit 
some characteristic features of craniometaphyseal dysplasia patients, including increased 
skull bone thickness, foramen magnum narrowing, middle ear bone fusion, and decreased 
trabeculation of femur metaphyses, but do not fully recapitulate other main features of the 
human disease
82
.  A new mouse model with a homozygous in-frame deletion in exon 9 of 
Ank more thoroughly resembles craniometaphyseal dysplasia; these mutant mice develop 
craniofacial and mandibular hyperostosis, obliteration of nasal sinuses, and flared 
metaphyses
165
.  Of note, craniometaphyseal dysplasia patients have heterozygous, not 
homozygous, mutations in ANKH
81
.  Mice harboring this knock-in mutation in the 
heterozygous state developed a mild skeletal phenotype by one year of age, but no other 
significant phenotypic differences.  Taken together, these findings suggest that ANKH 
mutations causing craniometaphyseal dysplasia are not merely loss of function and might 
in fact be dominant negative
82
.  Indeed, there is evidence to suggest that such mutations 
cause defects in osteoclastogenesis and bone resorption in addition to dysregulated PPi 
transport
166




Daily injections of phosphocitrate, a structural PPi analogue that potently inhibits 
hydroxyapatite formation
167
, block ectopic calcification and mitigate joint immobility in 
Ank complete knockout mice
168
.  Phosphocitrate prevented new calcification, but did not 
reverse already established calcification; importantly, there were no adverse effects on 
bone mineralization
168
.   
 
Ank knockout mice have a phenotype remarkably similar to that of Enpp1 knockout mice, 
although Enpp1 mutant mice have a more extensive hypermineralization phenotype, 
specifically in the phalanges, and develop pathology in other soft tissue areas, such as the 
Achilles tendon
169
.  Enpp1 and Ank deficient mice also have identical expansion of the 
acellular cementum
170
, the mineralized tissue that surrounds the tooth and anchors it to 
the periodontal ligament.  Since acellular cementum is highly sensitive to local PPi 
levels, these findings suggest that both ENPP1 and ANK act in resident cells to maintain 
tissue homeostasis
170,171
.   
 
Mice deficient for both Ank and Enpp1 qualitatively show more extensive vertebral 
column calcification than the single mutants alone
169
, suggesting that ANK and ENPP1 
have independent effects on extracellular PPi concentrations.  There is evidence that 
ENPP1 can function both extracellularly and intracellularly
172–174
, indicating that 
intracellular ENPP1 might be generating PPi for export by ANK.  Further studies with 
double Ank and Enpp1 deficient mice are currently underway to probe if ENPP1 and 
ANK work in series, in parallel, or both (personal communication with Drs. Brian L. 
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Foster and Emily Chu, College of Dentistry, The Ohio State University and National 
Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, respectively). 
 
Interestingly, mice with inactivating mutations in Ent1, which encodes a facilitative 
diffusion carrier responsible for the movement of hydrophilic nucleosides such as 
adenosine across the plasma membrane, also develop ectopic mineralization of the 
paraspinal ligament that extends into the intervertebral discs
175
.  While there is no known 
human equivalent, Ent1 mutant mice develop a strikingly similar phenotype to Enpp1- 
and Ank-deficient mice, though six months delayed
175
.  Ent1 mutant mice have increased 
circulating adenosine and PPi levels and decreased Alpl, Enpp1, and Ank expression in 
the local tissue that calcifies.  Adenosine decreases the expression of Alpl 
20
, the gene 
encoding TNAP, and this could explain the increased circulating PPi; however, it is 
unclear if the decreased expression of Enpp1 and Ank is primary or compensatory.  In any 
event, these overlapping mouse phenotypes illustrate the complex and poorly delineated 
intersection of PPi production and intracellular adenosine signaling. 
  
Tumoral calcinosis  
Tumoral calcinosis is caused by biallelic inactivating mutations in Galnt3, Fgf23, or 
Klotho; mouse models have been generated to disrupt these genes to define their function 
and probe the interaction of Pi-regulating factors in vivo.  Mutant mouse models develop 
hyperphosphatemia secondary to increased renal tubular Pi reabsorption with associated 
ectopic subcutaneous soft tissue and vascular calcification, in addition to increased or 
inappropriately normal 1,25-dihydroxyvitamin D levels
176–178
.  Galnt3 and Fgf23 mutant 
35 
 
mice have decreased serum concentrations of intact (functional) Fgf23 since their basic 
defect is in Fgf23 processing whereas Klotho deficient mice have elevated Fgf23 levels, 




By 12 weeks of age, the ENU-mutated Galnt3 mouse presents with widespread 
calcification in the cutaneous striated muscle, heart, kidney, tongue submucosa, and in 
the vasculature localized to the aorta and testis, and closely recapitulates the clinical 
features of tumoral calcinosis
177
.  The Galnt3 knockout mouse model, however, only 
develops ectopic calcification when provoked with a high Pi diet
180
.  Nicotinamide, 
which is hypothesized to lower serum Pi by decreasing activity of sodium-dependent Pi 
reuptake co-transporters in the gut
181
  and kidney
182
, was used to treat Galnt3 knockout 
mice initially fed a high Pi diet. Although the nicotinamide modestly prevented new 
calcification, it did not reverse existing calcium deposits and in fact increased calcium 
content in the heart.  It was shown that nicotinamide further decreased circulating levels 
of intact Fgf23, likely as a compensatory mechanism to increase Pi reabsorption in the 
kidney in response to the drug
183
.  These findings emphasize the tight regulation of this 
pathway.  
 
In addition to the common features of tumoral calcinosis, mice deficient in Fgf23 or 
Klotho also present with extensive occlusive aortic calcifications, vascular and 
parenchymal renal calcification, thickening and calcification of the auditory ossicles, 
pulmonary calcification with emphysematous changes, skin atrophy, osteopenia, 
hypercalcemia, hypoglycemia, and early death
176,178,184,185
.  The additional phenotypic 
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features and premature death of Fgf23 and Klotho deficient mice represent a more severe 
phenotype than that of patients with tumoral calcinosis, and suggest that rodent models, 
compared with humans, are more sensitive to disruptions in this pathway and less likely 
to compensate for deficiencies in Pi -regulating factors.   
 
However, these mouse models still provide valuable insights into disease mechanism and 
potential therapeutic interventions.  Fgf23 knockout mice fed a low Pi diet had decreased 
serum Pi and 50% of mutants survived longer, although they still demonstrated growth 
retardation, hypoglycemia and elevated 1,25-dihydroxyvitamin D levels; ectopic 
calcifications were not evaluated in this study
176
.  In a trial with more severe dietary 
restrictions of Pi, Pi deficiency corrected the hyperphosphatemia, prevented vascular 
calcification, and rescued the lethality in Fgf23 knockout mice
186
.   
 
Modulating vitamin D activity and levels has also been attempted as therapy for tumoral 
calcinosis mouse models. Genetically ablating vitamin D activity by knocking out the 
gene encoding an activator of vitamin D synthesis, 1α-hydroxylase, or inactivating the 
vitamin D receptor in Fgf23 knockout mice eliminates the soft tissue and vascular 
calcification and ameliorates other aspects of the phenotype including body weight, skin 
atrophy, and premature death
187–189
.  These genetic models corrected both the 
hyperphosphatemia and high vitamin D levels in the Fgf23 mutant mice and therefore did 
not assess the independent contributions of excessive serum Pi and vitamin D on vascular 
calcification.  Restricting only vitamin D in mouse models of tumoral calcinosis has had 
variable effects.  Lowering vitamin D by dietary restriction failed to correct the 
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hyperphosphatemia or the vascular calcification, although it did extend survival in Fgf23 
null mice
186
 while also preventing ectopic kidney calcification and restoring normal body 
weight in Klotho mutant mice
190
.  Taken together, these data implicate both Pi and 
vitamin D as predominant mediators of the tumoral calcinosis phenotype.  Although the 
therapeutic efficacy of lowering vitamin D levels remains unclear, these studies imply 
that decreasing Pi reduces ectopic calcification. 
  
In other studies, the mineralocorticoid receptor antagonist spironolactone reduced 
vascular and soft tissue calcification and slightly increased the lifespan of Klotho 
deficient mice, without significantly affecting circulating Pi, vitamin D, FGF23, or 
calcium concentrations
191
.  It has been suggested that spironolactone acts locally to 
decrease expression of genes involved in procalcific reprogramming and differentiation 
in the vessel wall
191
.  These data indicate that ectopic calcification is not controlled only 
by circulating Pi and calcium, but that cell-intrinsic factors also mediate pathologic 
calcification.  Recently, independent supplementation of sodium chloride, ammonium 
chloride, or bicarbonate also mildly attenuated tissue calcification and extended the 
lifespan of Klotho deficient mice
192–194
, suggesting that dysregulation of extracellular 
volume and pH can influence the disease phenotype.  
 
There is no mouse model for normophosphatemic familial tumoral calcinosis, since the 




Idiopathic basal ganglia calcification 
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Four genes, SLC20A2 (PIT2), XPR1, PDGFRB, and PDGFB, have been implicated in 
idiopathic basal ganglia calcification.  Homozygous Slc20a2 knockout mice present with 
brain calcification localized to arterioles, specifically in the thalamus, basal ganglia, and 
cortex, by 19 weeks of age
196
.  Slc20a2 knockout mice also developed microphthalmia, 
calcified cataracts and optic nerve tissue, and moderate to severe hydrocephalus, 
phenotypes not typically seen in idiopathic basal ganglia calcification patients
197
.  
Slc20a2 mice that are heterozygous for the knockout allele more closely recapitulate the 
human phenotype and develop brain vessel calcification later and without the additional 
manifestations of homozygous Slc20a2 knockout mice
197
.   
 
While serum Pi and calcium concentrations did not differ among wildtype, heterozygous, 
and homozygous Slc20a2 mice, cerebrospinal fluid Pi levels were trending high and were 
significantly increased in heterozygous and homozygous Slc20a2 mutant mice, 
respectively
197
.  Decreased phosphate import was also observed in vascular smooth 
muscle cells with experimentally knocked down Slc20a2, suggesting that the calcification 
phenotype is caused by a combination of high circulating Pi in the cerebrospinal fluid and 
defects in the local cell population
197
.  Slc20a2 mutant mice have not been subjected to 
behavioral or neuropsychiatric testing to see if calcification in brain arterioles leads to 
functional consequences.  Xpr1 mutant mice are commercially available but have not yet 
been evaluated for pathologic calcification or a corresponding phenotype. 
 
While mutations in Slc20a2 suggest that idiopathic basal ganglia calcification is caused 
by a combination of circulating and local disruptions in Pi homeostasis, mice completely 
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null for Pdgfrb and Pdgfb exhibit an inability of pericyte recruitment to developing 
microvessels; this leads to vascular dysfunction and perinatal death, and implicates a role 
for the blood-brain barrier maintenance in disease pathogenesis
198
.  Central and 
peripheral nervous system-specific Pdgfrb knockout mice have reduced social behavior 
and increased locomotor activity, reminiscent of some atypical neurological findings seen 
in idiopathic basal ganglia calcification patients; however, brain calcification was not 
reported
199
.  A mouse model with a hypomorphic allele of Pdgfb presented with calcific 
foci in the midbrain and thalamus at four months that expanded with age.  Although 
blood-brain barrier integrity was not directly tested, these hypomorphic Pdgfb mice were 
rescued by overexpression of PDGF-B in the endothelium
200
.  Supporting the role of 
blood-brain barrier defects in disease pathogenesis, fibrinogen depositions at autopsy 
have been associated with areas of calcification of one idiopathic basal ganglia 
calcification patient, indicating increased permeability of the blood-brain barrier.  
However, it is uncertain if this blood-brain barrier deficit is a cause or a consequence of 
the underlying pathology
201
.   
 
Also to note, knocking out Occludin, an integral tight junction component of the blood-
brain barrier, in mice results in cerebellar and basal ganglia calcification, similar to that 
seen in the mouse models of idiopathic basal ganglia calcification
202
.  Taken together, 
these findings strongly implicate Pi homeostasis
203
 and the PDGFB-PDGFRB signaling 
pathway
204
 in ectopic brain calcification.  Though the intersection of these pathways 
remains unclear, it has been reported that PDGFB increases the expression of Slc20a2 in 
culture
205





Homozygous ablation of Mgp, the gene encoding the vitamin K-dependent gamma 
carboxylated matrix Gla protein, results in extensive arterial and cartilaginous 
calcification in mice, recapitulating the Keutel syndrome phenotype
206
.  Calcification 
develops at approximately two to three weeks of age and is limited to elastic and 
muscular arteries and cartilaginous structures; the phenotype rapidly progresses and 
results in aortic rupture and death within two months
206
.  There is evidence of both elastic 





In addition to genetic ablation of the gene, matrix Gla protein has also been 
experimentally decreased by administration of exogenous warfarin, a vitamin K reductase 
inhibitor
207
.  Rats treated with warfarin and concurrent vitamin K1 had decreased 
extrahepatic vitamin K but normal vitamin K-dependent blood clotting factors and 
coagulation
207,208
.  Warfarin treatment resulted in extensive arterial calcification that did 
not regress when warfarin was removed
207
, but that did regress when the rats were 
repleted with vitamin K
209
.  Mice with deficiency of  osteoblast-specific Ggcx, the gene 
necessary for gamma-glutamyl carboxylase that, along with vitamin K, modifies and 
activates matrix Gla protein, also presented with aberrant calcification
210
.  Indeed, 
phenotypic similarities between the effects of genetic and environmental mediators of 






An ENU-mutated mouse model with a heterozygous gain-of-function mutation in Ifih1, 
which encodes the intracellular viral sensor MDA5 that has recently been associated with 
Singleton-Merten syndrome, predominantly develops lupus-like nephritis and systemic 
autoimmune symptoms without a viral insult
211
.  Although these mice do not closely 
recapitulate the Singleton-Merten phenotype, Ifih1 mutant mice develop spontaneous 
multiorgan inflammation and liver calcification
211
.  These mice have not been evaluated 
for a more extensive calcification phenotype.  
 
Chronic kidney disease, diabetes, and aging 
Common disorders of vascular calcification, including chronic kidney disease, diabetes, 
and aging, have also been studied in rodents.  Chronic kidney disease has been modeled 
by subjecting rodents to diets composed of high adenine, warfarin, or by partial or 
complete ablation of the kidneys, while calcification in chronic kidney disease models 
has been induced through diets high on vitamin D or Pi
212–214
.  These dietary and surgical 
provocations typically result in increased plasma concentrations of urea, Pi, and FGF23 
and cause extensive, though variable, medial vascular calcification, closely mimicking 
the reduced penetrance of vascular calcification-associated chronic kidney disease.   
 
Decreasing circulating Pi levels, attempted in a tumoral calcinosis mouse model, was also 
investigated in rodent models of chronic kidney disease.  Nicotinamide prevents the 
development of hyperphosphatemia by suppressing intestinal sodium-dependent Pi 
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transport in rats with adenine-induced renal failure
215
; however its effect on ectopic 
calcification was not evaluated.  Studies have shown that administering exogenous PPi 
via subcutaneous injection or continuous intraperitoneal infusion inhibits medial arterial 





Bisphosphonates have also been shown to prevent aortic calcification in uremic rats
17
.  
However, as in other vascular calcification disorders such as GACI and PXE, attempts to 
treat chronic kidney disease-induced vascular calcification with bisphosphonates required 
doses that disrupted bone mineralization and architecture
17
.  Additionally, the bone 
toxicity coupled with the fact that bisphosphonates require renal clearance has 
discouraged their use in chronic kidney disease
17
.   
 
Low-density lipoprotein receptor-null mice fed a high fat and cholesterol diet develop 
characteristics of metabolic syndrome including hypertension, obesity, dyslipidemia, and 





Mouse models recapitulating disorders of early aging also present with calcification.  
Knock-in Lmna mice recapitulate some of the clinical manifestations of Hutchinson-
Gilford progeria syndrome, an accelerated aging disorder that leads to premature death
221
.  
Lmna mutant mice show excessive aortic calcification.  Vascular smooth muscle cells 
derived from these animals have increased TNAP expression and activity and 
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subsequently reduced PPi levels and therefore a reduced capacity to inhibit in vitro 
calcification
221
.  Treatment of these mice with intraperitoneal injections of PPi inhibited 
vascular calcification
221
.  It has been questioned, however, if the rapid hydrolysis of PPi 




IV. DISEASE MECHANISMS  
Regulators of Calcification: Phosphate, Pyrophosphate, and Matrix Gla protein 
Mineralization of cartilage, bone, and tooth extracellular matrix is a physiological process 
whereas ectopic calcification is a pathological one.  Nevertheless, evidence suggests that 
ectopic calcification, like bone formation, is a highly regulated process involving both 
inductive and inhibitory processes.  These determinants include extracellular levels of 
calcium, the presence of a scaffolding extracellular matrix for mineral deposition, and the 
relative amounts of mineralization activators (e.g., Pi) and inhibitors (e.g., PPi and matrix 
Gla protein) present within the extracellular matrix environment.  Fetuin, osteopontin, 
and osteoprotegerin are also negative regulators of calcification, although data suggest 
that they are more actively involved in atherosclerosis and bone mineralization rather 
than ectopic calcification, and will not be discussed further
223
.  These factors are tightly 
balanced both in the circulation and in local microenvironments to maintain homeostasis 
and prevent pathologic calcification. 
 
Phosphate   
Pi is a major component and promoter of calcification.  In the presence of calcium, 
various calcium Pi salts are formed to neutralize the negative Pi ions; these amorphous 
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calcium Pi precipitates eventually form hydroxyapatite
224,225
.  In culture systems, high 
phosphate can induce osteochondrogenesis (see Osteochondrogenic Differentiation 
below).  In more common disorders of vascular calcification, serum phosphate is 




The role of Pi in pathologic calcification is most readily appreciated in patients with 
tumoral calcinosis, whose hyperphosphatemia leads to precipitation of Pi and calcium in 
ectopic tissue.  GALNT3, KLOTHO, and FGF23 are part of a tightly regulated Pi 
reabsorptive pathway (Fig. 7).  In the bone, GALNT3 O-glycosylates FGF23, preventing 
the proteolytic processing of FGF23, and therefore allowing the secretion of intact 
FGF23 into the circulation.  At the kidney, FGF23 binds to the FGFR1 receptor along 
with the co-receptor KLOTHO.  FGF23 signaling inhibits expression of renal 1α-
hydroxylase, thereby decreasing serum concentrations of 1,25-dihydroxyvitamin D and 
reducing intestinal inorganic Pi absorption.  In addition, FGF23 signaling downregulates 
the renal type 2 sodium-phosphate co-transporters (NaPi-2a and NaPi-2c), thereby 
decreasing renal tubular reabsorption of Pi
100
.  When this pathway is defective, there is 
increased Pi reabsorption from both the gut and the kidneys.   
 
The regulation of Pi is also seen in idiopathic basal ganglia calcification.  SLC20A2 is a 
sodium-dependent Pi importer, while XPR1 is a phosphate exporter
227,228
 (Fig. 8).  
Inactivating mutations in both genes cause idiopathic basal ganglia calcification 
emphasizing the tight regulation of Pi homeostasis.  XPR1 mutation-mediated calcium Pi 





Fig. 7.  The roles of GALNT3, FGF23, and KLOTHO in Pi homeostasis.  In the bone, 
GALNT3 glycosylates FGF23, preventing the proteolytic processing of FGF23, and 
therefore allowing the secretion of intact (active) FGF23 into the circulation.  At the renal 
tubular cell membrane, FGF23 binds to the FGFR1 receptor along with co-receptor 
KLOTHO.  FGF23 signaling inhibits expression of renal 1α-hydroxylase, thereby 
decreasing concentrations of 1,25-dihydroxyvitamin D in the circulation; this reduces 
intestinal Pi absorption.  FGF23 signaling also downregulates the renal type 2 sodium- Pi 
co-transporters (NaPi-2a and NaPi-2c) thereby decreasing renal tubular reabsorption of 
Pi.  When the FGF23 pathway is defective, there is increased Pi reabsorption from both 
the gut and the kidneys. 
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are thought to lead to deposition of calcium Pi in the extracellular matrix.  However, this 





PPi acts as a potent inhibitor of calcification; it antagonizes the ability of Pi to crystallize 
with calcium to form hydroxyapatite, presumably by occupying some of the inorganic Pi 
sites on the surface of nascent growing hydroxyapatite crystals; the irregularities created 
slow or terminate crystal growth
229
.  Three molecules (ENPP1, ANK, and TNAP) have 
been identified as central regulators of PPi levels (Fig. 9).   
 
ENPP1 is the primary source of extracellular PPi and hydrolyzes extracellular ATP into 
AMP and PPi
230
.  ENPP1 is a cell surface glycoprotein enzyme that functions in synergy 
with the multiple-pass transmembrane protein ANK which mediates intracellular to 
extracellular channeling of PPi
169
.  While ENPP1 is known to work extracellularly, it has 
been recently shown that soluble ENPP1 functions intracellularly and might also be the 




The extracellular concentration of PPi is further influenced by TNAP, another cell 
surface enzyme located on the membrane of cells and matrix vesicles.  TNAP exerts its 
effects by hydrolyzing PPi, reducing the concentration of this mineralization inhibitor and 





Fig. 8.  The regulation of Pi in idiopathic basal ganglia calcification.  SLC20A2, a 
sodium-dependent Pi importer, is predominantly expressed on cerebrospinal fluid-
producing cells surrounding the ventricle and on vascular smooth muscle cells 
encompassing vessels in the brain.  XPR1, a Pi exporter, is also expressed on vascular 
smooth muscle cells.  Inactivating mutations in SLC20A2 and XPR1 result in basal 
ganglia calcification emphasizing the tight regulation of Pi homeostasis.  While mutations 
in SLC20A2 lead to increased cerebrospinal fluid phosphate levels and dysfunction of 
local vascular smooth muscle cells which likely cause ectopic calcification in the 
extracellular matrix, XPR1 mutation-mediated calcium Pi precipitation has been 
suggested to occur intracellularly. 
48 
 





 PPi levels.  While calcification in GACI appears 
directly related to PPi deficiency, the vascular mineralization in ACDC patients involves 
a downstream metabolite, namely adenosine.  Adenosine signaling trophically inhibits 
ALPL expression
20,175
.  Impaired intracellular signaling mediated by adenosine receptors 
is considered responsible for the increased levels of TNAP in ACDC patient-cultured 
fibroblasts
20
.  Increased TNAP activity degrades extracellular PPi, promoting pathologic 
calcification.  
 
Levels of PPi are reduced in hemodialysis patients
233
 and correlate inversely with the 
amount of vascular calcification in patients with advanced chronic kidney disease
234
.  
Circulating PPi levels are primarily reduced, most likely because of increased alkaline 
phosphatase activity in the vessel wall.  Consistent with these findings, intact aortas and 
aortic homogenates from uremic rats showed a substantial increase in TNAP enzyme 
activity
235
.   
 
PPi is considered a potent inhibitor of calcium Pi crystal formation, but when present at 
high levels, PPi itself can precipitate with calcium ions to form an alternative type of 
crystal called CPPD.  Indeed, gain-of-function mutations in ANKH cause 








Fig. 9.  Schematic representation of the predominant enzymatic reactions and 
transported substrates in local cells involved in ectopic calcification.  ENPP1 breaks 
down ATP into AMP and PPi.  ANK transports PPi out of the cell, also contributing to 
extracellular PPi levels.  CD73 further degrades AMP into adenosine and Pi.  ABCC6 is 
integral to the extracellular ATP metabolism pathway, though its substrate and function 
remain elusive.  Adenosine can be transported into the cell by ENT1 or bind to a cell 
surface adenosine receptor to promote a number of diverse downstream actions, including 
repression of ALPL, the gene encoding TNAP.  TNAP degrades PPi into Pi and is a 
primary distal regulator of Pi and PPi homeostasis.  Matrix vesicles bud off of local cells 
and accumulate Pi through SLC20A1 and calcium though annexins.  Calcium and Pi 
precipitate as a nidus of calcification inside the matrix vesicles.  Continued calcium- Pi 
accumulation eventually leads to matrix vesicle breakage and propagation of 
hydroxyapatite in the extracellular space. 
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Matrix Gla protein 
Matrix Gla protein is recognized as a potent local inhibitor of vascular calcification
140,236
.  
To be fully functional, matrix Gla protein requires posttranslational modification by a 
gamma-carboxylase, a vitamin K-dependent protein that is inhibited by warfarin.  
Interestingly, only when matrix Gla protein is overexpressed in vascular smooth muscles 
cells–instead of the liver–does it inhibit calcification in vivo, strongly suggesting that 




Matrix Gla protein binds to calcium and is secreted by chondrocytes and vascular smooth 
muscle cells
206
.  It directly inhibits calcification, co-localizing with elastin in the arterial 
elastic lamina and physically disrupting calcium-phosphate deposition
238
.  Matrix Gla 
protein also sequesters bone morphogenic protein (BMP), specifically BMP2, in vitro and 
subsequently inhibits vascular BMP signaling and osteogenic differentiation
239
; it is 
unclear if this process is relevant in vivo.   
 
Local versus Circulating Hypotheses 
Pi, PPi, and matrix Gla protein have been widely accepted as regulators of ectopic 
calcification, largely because they also function in the physiologic mineralization of 
skeletal hard tissues. There is considerable controversy, however, concerning the relative 
contribution of these factors from the local microenvironment versus the circulation.  
Determining the biologically relevant tissues and/or cell types producing these factors has 




The protein defective in PXE, ABCC6, is a member of the multidrug resistant protein 
family, with known transporter activity
240
, but its endogenous substrate remains elusive.  
The ABCC6 protein has very low expression in the peripheral cells directly affected in 
PXE, i.e., dermal fibroblasts and vascular smooth muscle cells
241
, but strong expression 
in the liver
242
 and, to a lesser extent, kidney.  This has led to the prevailing hypothesis 
that ABCC6 exports an endocrine inhibitor of calcification that acts at distant target 
sites
243
, but only circumstantial evidence exists for this “metabolic” theory (Fig. 10).  
Specifically, a wildtype muzzle transplanted onto the back of an Abcc6 mutant mouse 
developed ectopic calcification in the fibrous capsule surrounding the vibrissae
244
.  It is 
unclear if the observed calcification completely recapitulates the PXE mouse model 
phenotype since the extent of calcification of an Abcc6 mutant muzzle transplanted onto 
an Abcc6 knockout mouse was not investigated. In another study, parabiosis between 
Abcc6
 
mutant and wildtype mice in which the two circulations were connected showed 
attenuation of the calcification phenotype in the mutant mouse compared to that seen in 
the parabiosis of two Abcc6 mutant mice
245
.  If PXE is solely driven by a circulating 
factor, however, it would be expected that both the mutant mouse and wildtype mouse 
would have the same degree of calcification since they were paired before the onset of 
the phenotype; however, there was no calcification observed in the wildtype mouse when 
the Abcc6
 
mutant and control mice were paired.  Taken together, these data suggest that a 
defect in a circulating factor is sufficient to induce ectopic calcification and repletion of 
this factor diminishes the phenotype.  However, since the Abcc6 mutant mouse in the 





Fig. 10.  The contribution of circulating factors in PXE pathogenesis.  The lack of 
knowledge pertaining to the substrate transported by ABCC6 complicates our 
understanding of PXE.  The strong expression of ABCC6 in the liver has led to the 
prevailing hypothesis that hepatocellular ABCC6 exports an endocrine inhibitor of 
calcification that acts at distant target sites.  However, recent evidence (discussed in 
Chapter 4) suggests that local cells might be involved in PXE pathogenesis.  It has been 
shown that PXE patients and mice have decreased circulating PPi levels.  Low PPi could 
be indirectly mediated by the actions of ENPP1 in the liver, or as a consequence of high 
TNAP activity in local cells.  A unifying hypothesis would propose that mutations in 
ABCC6 make local cells vulnerable to decreased circulating PPi. 
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wildtype mouse did not, this indicates that another factor, perhaps a local cell, might also 
be involved in PXE-related calcification. 
 
Dermal fibroblast cell lines derived from PXE patients are morphologically and 
biochemically distinct from controls; they have higher proliferation rates, decreased cell-
cell and cell-matrix adhesion properties, and altered synthesis of connective tissue 





mutant cells also produce 30% less matrix Gla 
protein compared to controls
248
.  Finally, ABCC6
 
mutant cells have a tendency for matrix 
mineralization and an altered metabolic profile, including higher gene expression of the 
PPi metabolizing enzymes, TNAP
249
.   
 
Some scientists contend that these cultured fibroblast-specific changes are due to 
persistence of a circulating factor that impairs the function of the fibroblasts in vitro
250
; 
however, it is also possible that there are inherent, cell-autonomous defects in PXE 
patient-derived cells.  Indeed Abcc6 mutant zebrafish showed signs of excessive 
pathologic calcification and Abcc6 gene expression was localized to sites of ectopic 
calcification, specifically in osteoblasts, instead of the liver
251
.   
 
The lack of knowledge pertaining to the substrate transported by ABCC6 complicates our 
understanding of PXE pathogenesis.  It has recently been proposed that ABCC6 
indirectly mediates ATP transport from the liver, which is then immediately broken down 
into AMP and PPi
252
, implicating PPi as the circulating metabolic factor missing in PXE 
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(Fig. 10).  In support of this hypothesis, it has been established that there are decreased 
levels of circulating PPi in PXE mice and humans.  However, low levels of PPi could 
also be a result of high TNAP activity, which has been observed in ABCC6-deficient 
cells. 
 
A unifying hypothesis would propose that mutations in ABCC6 make local cells (such as 
vascular smooth muscle cells or fibroblasts; Fig. 9) vulnerable to decreased circulating 
PPi, which is mediated by transport from the liver (Fig. 10).  This hypothesis would 
reconcile the published results showing that there is low circulating PPi with the data 
demonstrating a cell-autonomous phenotype.   
 
The dispute between circulating and local factors is also apparent in the disease 
pathogenesis underlying idiopathic basal ganglia calcification.  Slc20a2 knockout mice 
have high Pi levels in the cerebrospinal fluid compared to control mice
197
  because of 
decreased Pi reuptake in cerebrospinal fluid-generating tissues, including the choroid 
plexus and ependyma (Fig. 8).  It has also been shown that Slc20a2 is expressed locally 
in vascular smooth muscle cells, but not in pericytes or endothelial cells.  When Slc20a2-
deficient vascular smooth muscle cells are exposed to osteogenic media in vitro, they 
have an increased susceptibility to calcification.  Thus, basal ganglia calcification may be 
caused by the combination of abnormal cerebrospinal fluid Pi homeostasis and increased 
susceptibility of vascular smooth muscle cells
197




These examples illustrate that both circulatory and local factors are necessary to maintain 
tissue homeostasis.  In PXE, there is a circulatory deficit of blood PPi whereas in 
idiopathic basal ganglia calcification there is excess Pi in the cerebrospinal fluid.  In both 
diseases, local cells are sensitized by their basic genetic defects to the circulating 
imbalances, resulting in pathologic calcification.   
 
Osteochondrogenic Differentiation 
While dysregulation of PPi and Pi may directly lead to precipitation of calcium Pi and 
eventual hydroxyapatite formation, local changes in PPi and Pi homeostasis might also 
trigger cell-mediated mineralization, acceleration of the calcification process, and 
potential for ossification and/or chondrification.  Transdifferentiation of vascular smooth 
muscle cells into osteochondrocyte-like cells has been reported in the media of calcified 
vessels of rare diseases (e.g., Keutel syndrome
139,206
) and common disorders, such as 
chronic kidney disease, type 2 diabetes, and patients on dialysis
220,253–256
.  These cells 
express bone and/or cartilage-specific proteins, such as TNAP, which often co-localize 
with calcium-Pi minerals in the vessel wall
253
.  Matrix vesicles, which accumulate 
calcium and Pi and eventually become the nidus for calcification, have also been 
identified in situ in these sites of calcification
257
.   
 
In vitro, cells derived from the arterial media, mainly vascular smooth muscle cells, 
undergo osteochondrogenic differentiation in response to elevated Pi levels by increasing 
expression of bone regulatory proteins while simultaneously downregulating markers of 
smooth muscle lineage
258,259
.  Specifically, when stimulated with inorganic phosphate, 
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these cells express the sodium-dependent phosphate transporter (SLC20A1) which 
induces the early osteogenic/chondrogenic transcription factor RUNX2
254,260
.  In addition 
to Pi dysregulation, a number of other signaling pathways have been implicated in 
directly promoting osteochondrogenic differentiation, including BMP2
261
 and PDGF-BB 
signaling through PDGFRB
262
.  These osteochondrocyte-like cells elaborate matrix 
vesicles
263
 and eventually mineralize their extracellular matrix, much like the 
physiological conditions driving bone formation
264
.   
 
There is conflicting evidence pertaining to the onset of lineage reprogramming in the 
context of pathologic calcification.  Some evidence suggests that osteochondrogenic 
differentiation occurs before calcium deposition, such as in matrix Gla protein-null mice 
where calcified cartilaginous lesions originate from phenotypically transformed vascular 
smooth muscle cells
264
.  However, other reports indicate that while cells with 
osteochondrocyte-like morphology are resident in the calcified aorta, osteochondrogenic 
markers are not upregulated in the arteries prior to the initiation of calcification
265
.   
 
To probe the relative contributions of osteochondrogenic transdifferentiation versus 
calcium Pi deposition, the Mgp-null mouse was independently bred to transglutaminase 2 
and Elastin knockout mice.  Knocking out transglutaminase 2, a promoter of BMP 
signaling, in matrix Gla protein-null mice decreased calcification presumably by 
inhibiting the phenotypic transdifferentiation of vascular smooth muscle cells into 
osteochondrocyte-like cells
266
.  Elastin haploinsufficiency in matrix Gla protein -null 
mice also significantly reduced arterial calcification
265
.  Indeed, both genetic crosses 
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reduced calcification, indicating that these processes are co-existent and likely both 
necessary to promote ectopic calcification.   
 
Despite the controversy over whether osteochondrogenic differentiation is an inciting 
event or a consequence of ectopic calcification, complete ossification or chondrification 
only occurs in a minority of diseased arteries.  While bone and cartilage have been 
observed in vessels from mice with Mgp deficiency
206
, long-standing diabetes, and renal 
failure
267,268
, bone or cartilage metaplasia has not been seen in any other disorders of 
ectopic calcification.  This is possibly because of slower angiogenic invasion or the 
greater abundance of elastin, which maintains the smooth muscle cell phenotype
269
.  
Additionally, this cellular differentiation process might be attenuated in this disease 
context, maintaining only partial capacity for bone or cartilage formation. 
 
Viral Mechanisms 
There is also evidence that implicates the disruption of the viral maintenance machinery 
in ectopic calcification.  MDA5, encoded by IFIH1, is a member of the RIG-1-like 
receptor family and functions as a cytoplasmic pattern-recognition receptor recognizing 
viruses, double-stranded RNA, and secreted bacterial nucleic acids
270
.  How these 






The balance between Pi and PPi, in addition to other factors, is strictly controlled by a 
complex interplay of genes and plays an undisputed role in ectopic calcification.  
Understanding this homeostasis and the pathways involved will help us better identify 
new treatment targets and design therapeutic strategies. Insights into rare diseases should 












































Arterial calcifications are associated with increased cardiovascular risk, but the genetic 
basis of this association is unclear. 
Methods 
We performed clinical, radiographic, and genetic studies in three families with 
symptomatic arterial calcifications. Single-nucleotide-polymorphism analysis, targeted 
gene sequencing, quantitative polymerase-chain-reaction assays, Western blotting, 
enzyme measurements, transduction rescue experiments, and in vitro calcification assays 
were performed. 
Results 
We identified nine persons with calcifications of the lower-extremity arteries and hand 
and foot joint capsules: all five siblings in one family, three siblings in another, and one 
patient in a third family. Serum calcium, Pi, and vitamin D levels were normal.  Affected 
members of Family 1 shared a single 22.4-Mb region of homozygosity on chromosome 6 
and had a homozygous nonsense mutation (c.662C→A, p.S221X) in NT5E, encoding 
CD73, which converts AMP to adenosine.  Affected members of Family 2 had a 
homozygous missense mutation (c.1073G→A, p.C358Y) in NT5E.  The proband of 
Family 3 was a compound heterozygote for c.662C→A and c.1609dupA (p.V537fsX7).  
All mutations found in the three families result in nonfunctional CD73.  Cultured 
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fibroblasts from affected members of Family 1 showed markedly reduced expression of 
NT5E messenger RNA, CD73 protein, and enzyme activity, as well as increased alkaline 
phosphatase levels and accumulated calcium Pi crystals.  Genetic rescue experiments 
normalized the CD73 and alkaline phosphatase activity in patients' cells, and adenosine 
treatment reduced the levels of alkaline phosphatase and calcification. 
Conclusions 
We identified mutations in NT5E in members of three families with symptomatic arterial 
and joint calcifications.  This gene encodes CD73, which converts AMP to adenosine, 
supporting a role for this metabolic pathway in inhibiting ectopic tissue calcification. 
 
II. INTRODUCTION 
Vascular calcification, arising either in the intima or media of vessels, is associated with 
an excess risk of cardiovascular events
271,272
.  This was initially considered a passive 
response to degenerative events, but mounting evidence suggests it is the result of a 
process that mimics active bone remodeling
273,274
.  Extracellular calcification is 
increasingly viewed as arising from a default biochemical default pathway and requiring 
the constant stimulation of inhibitory systems to prevent its occurrence. 
 
Only a single Mendelian disorder of isolated vascular calcification ˗ idiopathic infantile 
arterial calcification, now also referred to as generalized arterial calcification of infancy 
(GACI) ˗ has been described
4
.  This autosomal recessive disease, due to mutations in the 
ectonucleotide pyrophosphatase phosphodiesterase 1 gene (ENPP1), often results in 
death during childhood, apparently owing to disruption of the trophic influences that 
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inhibit vascular-cell calcification.  We conducted a study to evaluate an adult-onset 
disorder in three families whose affected members had extensive calcifications of the 
lower-extremity arteries and small joint capsules and to investigate a possible genetic 




Family 1 was of English descent.  The proband (Fig. 11A), Patient VI.1, was a 54-year-
old woman with a 20-year history of intermittent claudication of the calves, thighs, and 
buttocks and chronic ischemic pain in the feet at rest.  Her parents were third cousins.  On 
evaluation at the NIH, her ankle–brachial blood-pressure index values were markedly 
reduced, but the levels of serum calcium, Pi, vitamin D, alkaline phosphatase, creatinine, 
and cholesterol, and other chemical values were normal (Table 1). Contrast-enhanced 
magnetic-resonance angiography revealed extensive occlusion of the iliac, 
femoropopliteal, and tibial arteries, with extensive collateralization.  Plain radiography of 
the lower extremities revealed heavy calcification with areas of arteriomegaly (Fig. 11B 
and 11C); chest radiography revealed no vascular calcifications above the diaphragm.  
Radiography also revealed juxta-articular joint-capsule calcifications of the fingers (Fig. 
11D), wrists, ankles, and feet. 
 
All four siblings of Patient VI.1 had disabling intermittent claudication (ability to walk 
only 1 to 6 blocks) and hemodynamically significant lower-extremity obstructive 




Fig. 11. Pedigrees of the study patients and radiographic findings.  (A) The pedigrees 
of the three study families.  Open symbols indicate unaffected family members, and solid 
red symbols affected members.  Arrows indicate the probands.  Squares indicate male 
family members, circles female members, slashes deceased members, and double 
horizontal lines consanguinity.  The diamond indicates offspring of unknown number, 
and the triangle a lost pregnancy.  (B) Plain radiographs of popliteal arteries of the three 
probands.  (C) Plain radiographs of the pelvis and femurs (left) and ankle (right) of 
Patient VI.1 of Family 1, revealing calcified arteries (arrow).  (D) Radiographs of 




between 0.3 and 0.8 (normal range, 1.0 to 1.3).  All had extensive femoropopliteal 
occlusion evident on magnetic-resonance arteriography, with diffuse, mild aneurysmal 
remodeling in a pattern of arteriomegaly.  Computed tomographic (CT) angiography in 
three of the siblings showed that the obstructive lesions were diffusely and heavily 
calcified.  Whole-body CT scanning for calcium, performed in one sister (Patient VI.5), 
showed prominent circumferential vascular calcifications in the lower extremities; CT 
angiography revealed extensive vascular obstruction with diffuse calcification (see the 
video, available at NEJM.org). 
 
The proband of Family 2 (Fig. 11A), Patient II.4, was a 68-year-old northern Italian 
woman whose mother’s surname was the same as that of some of her father’s relatives 
four generations ago. She reported having intense joint pain in her hands that was 
unresponsive to glucocorticoids administered from 14 to 27 years of age.  Radiographs of 
the lower limbs revealed calcifications (Fig. 11B), initially diagnosed as 
chondrocalcinosis.  Serum electrolyte, calcium, and cholesterol levels were normal.  Two 
sisters, 73 and 70 years of age (Fig. 11A), also had lower-extremity pain and had vascular 
calcifications that were similar to those of the proband. 
 
The proband of Family 3 (Fig. 11A), Patient II.1, was a 44-year-old woman with an 
English father and a French mother.  At 42 years of age, mild paresthesias in the lower 
legs prompted an evaluation that revealed extensive calcifications of the distal arteries 
(Fig. 11B), with sparing of the carotid arteries, aorta, and coronary arteries.  Extensive 




Table 1.  Clinical characteristics of affected members of Family 1.  
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leg prompted a femoral–popliteal bypass at 43 years of age.  Serum C-reactive protein, 
cholesterol, lipid, calcium, Pi, and vitamin D levels were within the normal range. 
 
None of the nine affected patients and none of their parents or children had abnormal 
bone morphologic characteristics, type 2 diabetes mellitus, or decreased kidney function.  
The parents of the five siblings in Family 1 had no clinically significant calcifications in 
their lower extremities or joint capsules. 
 
SNPs, mutation analyses, and expression studies 
We identified biallelic nonsense, missense, and single-nucleotide insertion–frameshift 
mutations in the ecto-5′-nucleotidase gene NT5E, encoding the CD73 enzyme, which 
generates extracellular adenosine, directly downstream of ENPP1 in the extracellular 
ATP–degradation pathway. 
 
The consanguineous pedigree of Family 1, with disease confined to one generation (Fig. 
11A), suggested autosomal recessive inheritance.  Therefore, we searched for a region of 
the genome in which all five affected siblings were homozygous and identical by means 
of descent but in which both parents were heterozygous.  There was only one such region 
in the entire genome: a 22.4-Mb region (Fig. 12A) on chromosome 6q14 (86,157,551 to 
108,573,717 bp), containing 7977 genotyped SNPs and 92 genes.  The lod score for the 





Of the 92 genes in this region, three were evaluated: ATG5 and CASP8AP2 because they 
are involved in degenerative cellular processes that could lead to calcification, and NT5E 
because its enzyme substrate is the product of ENPP1, mutations in which cause arterial 
calcifications in infants
4
.  Direct sequencing identified a homozygous nonsense mutation 
(c.662C→A, resulting in p.S221X) in exon 3 of the NT5E gene in all five siblings of 
Family 1 and the same nonsense mutation in the heterozygous state in both parents (Fig. 
12B).  Quantitative PCR analysis documented decreased expression of NT5E messenger 
RNA in the fibroblasts of Patients VI.1 and VI.4 in Family 1 (Fig. 12C). Affected 
members of Family 2 were homozygous for a missense mutation, c.1073G→A 
(p.C358Y), in exon 5 of NT5E; the mother was heterozygous for this variant of the amino 
acid, which is conserved across 16 species.  The affected member of Family 3 was a 
compound heterozygote for the c.662C→A nonsense mutation found in Family 1 and a 
c.1609dupA (V537fsX7) mutation leading to a premature stop codon in exon 9 of NT5E.  
None of these mutations was present in 400 alleles in ethnically matched controls. 
 
Protein and enzyme activity 
NT5E encodes CD73, a membrane-bound ecto-5′-nucleotidase (specifically, 5′–
ribonucleotide phosphohydrolase; EC 3.1.3.5) involved in extracellular ATP metabolism. 
The enzyme preferentially binds AMP and converts it to adenosine and Pi
275
.  Protein 
analysis involving Western blotting of fibroblast extracts from Patients VI.1 and VI.4 of 
Family 1 revealed markedly reduced expression of CD73 protein, as compared with 
normal controls.  An enzymatic assay of CD73 in fibroblasts from our patients revealed 




Fig. 12.  Results of genetic and enzyme studies in Family 1.  (A) SNP–array 
homozygosity plots for the five affected siblings in Family 1 and their parents.  (B) 
Sequence chromatograms for a control, a parent of an affected member of Family 1, and 
an affected member.  (C) NT5E messenger RNA expression in Patients VI.4 and VI.1 as 
compared with controls.  (D) Deficiency in CD73 enzyme activity in cultured fibroblasts 
from Patient VI.4 and Patient VI.1 of Family 1.  (E) CD73 enzyme activity in fibroblasts 
from controls and from Patient VI.4 after the fibroblasts were transduced with either an 
empty vector or a CD73-containing vector.  (F) CD73 activity in HEK293 cells 
transfected with an empty vector or a vector containing wildtype NT5E or mutant NT5E. 
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approximately 72% of the control level.  Genetic rescue with a CD73-encoding lentiviral 
vector reestablished normal AMP-dependent Pi production (Fig. 12E).  The enzymatic 
activities of normal and mutant CD73 constructs were tested in HEK293 cells, which 
have low endogenous CD73 activity.  Transfection with normal NT5E cDNA resulted in 
abundant CD73 activity, whereas transfection with the c.662C→A NT5E, c.1073G→A 




A key enzyme in tissue calcification in vitro and in vivo is tissue-nonspecific alkaline 
phosphatase (TNAP)
161
.  After 3 days of calcific stimulation, fibroblasts from Patient 
VI.4 of Family 1 stained abundantly for TNAP, as compared with control cells; treatment 
with adenosine substantially reduced the amount of TNAP staining (Fig. 13A).  TNAP 
activity was also assayed in the lysates of fibroblasts grown in calcifying medium.  As 
compared with control cells, cells from Patient VI.4 showed high levels of TNAP that 
were significantly reduced after transduction with CD73-encoded lentiviral vector or by 
adenosine treatment (Fig. 13B).  Three weeks of calcific stimulation resulted in abundant 
calcium Pi crystal formation in mutant fibroblasts (from Patient VI.4) but no formation in 
normal fibroblasts (Fig. 13C).  Calcium Pi crystal formation was prevented in cells 
transduced with a CD73-encoding lentiviral vector but not control vector expressing β-
galactosidase.  Adenosine treatment largely abrogated the calcification process, and the 
noncompetitive alkaline phosphatase inhibitor levamisole completely prevented 




Fig. 13. Studies of fibroblasts obtained from Patient VI.4 of Family 1.  (A) Staining 
for TNAP in fibroblasts from a control and from Patient VI.4.  The increased staining in 
the patient’s cells was reduced by adding 30 μM adenosine.  (B) TNAP activity in 
fibroblasts from a control and from Patient VI.4.  Transduction with a control vector 
expressing β-galactosidase had little effect on alkaline phosphatase activity, whereas 
transduction with a CD73-encoding vector reduced alkaline phosphatase activity 
significantly; incubation in 30 μM adenosine produced TNAP levels similar to those seen 
in control cells.  (C) The effects of interventions on calcium Pi crystal formation in 
fibroblasts from a control and from Patient VI.4.  Calcium staining was prevented by 
transduction with a CD73-encoding lentiviral vector and by treatment with 1 mM 




Medial arterial calcification of the lower extremities with periarticular calcification was 
described first by Magnus-Levy
276
 in 1914 and again by Levitin
277
 in 1945. The familial 
nature of this condition was first suggested in a report on two affected siblings by 
Sharp
278
 in 1954, leading to a subsequent record in the Online Mendelian Inheritance in 
Man database (OMIM number, 211800).  Other, single cases were described by Nosaka 
and colleagues and Mori and coworkers
279
, yielding a total of seven cases published to 
date.  Here, we describe the molecular and enzymatic basis of this disorder in nine 
patients with three different mutations in NT5E. 
 
Considerable evidence supports the association of these families’ vascular disease with 
mutations in the NT5E gene.  The results of segregation analysis were consistent among 
our families, and the nonsense mutation (p.S221X) and single-nucleotide insertion 
(p.V537fsX7) predict truncated CD73 proteins.  The missense mutation (p.C358Y), 
which was not found in 200 unaffected persons, predicts a pathologic change in an amino 
acid conserved through evolution and is located in the critical nucleotidase domain of 
CD73.  Furthermore, the nonsense mutation resulted in markedly reduced levels of CD73 
mRNA and protein in cultured cells.  Enzyme activity was virtually absent in fibroblasts 
from affected members of Family 1 and was rescued by transduction of a lentiviral vector 
expressing NT5E.  Each of the three different mutations in the three families produced 
essentially nonfunctional CD73. 
 




Fig. 14. Proposed mechanism of mineralization due to CD73 deficiency from an 
NT5E mutation.  On the surface of vascular cells, ENPP1 (the protein encoded by the 
ectonucleotide pyrophosphatase–phosphodiesterase 1 gene) converts ATP to AMP and 
PPi, and CD73 converts AMP to adenosine and inorganic phosphate (Pi).  PPi inhibits 
calcification, TNAP degrades PPi, and adenosine inhibits TNAP.  Deficiency of CD73 
results in decreased adenosine levels, eliminating the inhibition of TNAP from the 
pathway either directly or by way of adenosine receptor signaling. Increased TNAP from 







surface of various types of cells, as follows.  First, ENPP1 produces AMP and PPi from 
ATP; then CD73 produces adenosine and Pi from AMP (Fig. 14).  Cellular calcification 
depends critically on levels of pyrophosphate, a strong inhibitor of calcification, and 
TNAP, which degrades PPi
161
.  In patients with hypophosphatasia due to TNAP 
deficiency, increased levels of PPi result in defective bone mineralization
280
.  In patients 
with generalized arterial calcification of infancy, ENPP1 deficiency leads directly to 
decreased PPi levels
169
, causing early-onset vascular calcification, myocardial infarction, 
and often death in infancy
4
.  In our adult patients, CD73 deficiency may not lead directly 
to decreased PPi levels, but the consequent reduction in extracellular adenosine levels 
apparently enhances TNAP activity; adenosine supplementation reversed the increase in 
TNAP activity in CD73-deficient cells.  We hypothesize that increased TNAP activity 
reduces PPi levels, leading to calcification; indeed, levamisole, an inhibitor of TNAP, 
prevented calcium crystal formation by CD73-deficient fibroblasts.  The selective 
involvement of lower-extremity arteries may be related to the particular distribution of 




Knowledge of the basic defect in our patients allows for consideration of therapeutic 
interventions.  Bisphosphonates, which are PPi analogues and potent inhibitors of tissue 
calcification, have been successfully used to treat ENPP1 deficiency and might prove 
beneficial in patients with CD73 deficiency
6,282
.  Dipyridamole, an antithrombotic drug 
used successfully in patients with aneurysmal vascular remodeling, could provide 
adenosine rescue, since it inhibits cellular reuptake of adenosine (and subsequent 
degradation by adenosine deaminase) both in vitro and in vivo
283
.  Other therapeutic 
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possibilities include the use of adenosine-receptor agonists or a direct inhibitor of TNAP 
such as lansoprazole
284,285
.  The potential efficacy of such interventions can be 
investigated in cultured cells, which exhibit both TNAP and calcification phenotypes that 
are abrogated by transduction with a CD73-encoded lentiviral vector.  Mice with CD73 
deficiency can also be studied, if a calcification phenotype can be discerned
286,287
, to 
elucidate the role of adenosine in regulating vascular calcification, influencing bone 
mineralization, and modulating ectopic calcium deposition. 
 
In summary, we identified mutations in NT5E in members of three families with 
symptomatic arterial and joint calcifications. This gene encodes CD73, a nucleotidase 
that converts AMP to adenosine. Thus, our results support a role for this metabolic 




Three families were studied. Members of Family 1 and Family 3 were admitted to the 
National Institutes of Health (NIH) Undiagnosed Diseases Program and enrolled in 
clinical studies whose protocols had been approved by the institutional review board of 
the National Human Genome Research Institute.  The genetic studies for Family 2 were 
approved by the institutional review board of Azienda Ospedaliera Universitaria San 
Giovanni Battista.  All subjects provided written informed consent. 
 
Fibroblast cell cultures 
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Fibroblast cultures were prepared from a 4-mm punch-biopsy skin specimen obtained 
from each patient and grown in Dulbecco’s modified Eagle’s medium containing 10% 
fetal-calf serum and 1% penicillin–streptomycin, as previously described
288
.  Cells were 
fed every other day and split 1:2 at confluence. 
 
SNP array analysis 
Genomic DNA in Family 1 was isolated from peripheral leukocytes and genotyped on a 
genotyping array (Human 1M Duo, Illumina).  Homozygosity-allele plots were generated 
with the use of GenomeStudio software.  Anomalous regions of homozygosity were 
identified visually and confirmed by means of haplotype imputation (ENT program).  A 





Mutation analysis of CD73 
Coding exons and intron–exon junctions of NT5E were amplified with the use of a 
touchdown polymerase-chain-reaction (PCR) assay of 50 ng of genomic DNA, 3 µM of 
sense and antisense oligonucleotides, and 5 µl of HotStart Master Mix (Qiagen) in a final 
volume of 10 µl.  PCR products were sequenced in both directions with the use of the Big 
Dye terminator kit (version 1.1, Applied Biosystems) and an automated capillary 
sequencer (ABI PRISM 3130xl Genetic Analyzer, Applied Biosystems).  We compared 
electrophoretogram-derived sequences with reference sequences for NT5E (Ensembl gene 
number ENSG00000135318) by using Sequencher software (version 4.8). Screening of 
200 DNA samples from controls of white race (panel HD200CAU, Coriell Cell 
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Repositories) was performed by means of the 5′–nuclease allelic discrimination 
(TaqMan) assay, as previously described
290
.  Details of the PCR amplification, primer 
sequences, and allelic discrimination assay are available in the Supplementary Appendix, 
available with the full text of this article at NEJM.org. 
 
Expression studies 
RNA was isolated from cultured fibroblasts with the use of the RNeasy kit (Qiagen), and 
complementary DNA (cDNA) was generated from 1-µg RNA samples with the use of the 
SuperScript II Reverse Transcriptase kit (Invitrogen).  Expression of NT5E was measured 
by means of a quantitative real-time PCR assay involving SYBR Green technology on a 
Chromo4 Real Time PCR Detection System (Bio-Rad).  Expression levels were 
calculated on the basis of the 2−ΔCt method, in which the cycling threshold (Ct) of the 
candidate gene is compared with the Ct of 18S ribosomal RNA and expressed as a power 
of two (2(Ct of NT5E −Ct of 18S)). 
 
Western blotting for CD73 
Cells were grown to confluency, trypsinized, pelleted, and lysed by addition of 50 mM 
Tris-HCl pH7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40 and 0.1% SDS (RIPA buffer) 
supplemented with 0.5% Triton-x 100 and 1x Complete Mini Protease Inhibitor Cocktail 
(Roche).  After 10 min on ice, the lysate was vortexed at 4
o
C for 5 min and centrifuged at 
15,000 x g and supernatant protein quantified using the bicinchoninic acid assay (Pierce).  
Thirty mg of protein was mixed with SDS protein gel loading solution (Quality 
Biologicals), loaded on a 4-20% polyacrylamide gel (Bio-Rad), and electrophoresed at 
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120V for 1.5 h.  After protein transfer, antibodies against CD73 (Abcam) and actin 
(Sigma-Aldrich) were used at dilutions of 1:1000 and 1:50,000, respectively. 
 
CD73 enzyme assay 
Fibroblasts were washed with a solution of 2 mM magnesium chloride, 120 mM sodium 
chloride, 5 mM potassium chloride, 10 mM glucose, and 20 mM HEPES.  Incubation 
buffer, consisting of the wash solution supplemented with 2 mM AMP, was added, and 
cells were incubated at 37 °C for 10 minutes
291
.  The supernatant was removed, and Pi 
was measured with the SensoLyte MG Phosphate Assay Kit (AnaSpec) according to the 
manufacturer’s instructions.  Pi measurements were normalized to micrograms of protein. 
 
Cloning of mutations and production of lentivirus 
The plasmid pCMV-Sport6 containing human CD73 cDNA was purchased from Open 
Biosystems.  Mutations were introduced by means of the QuikChange XL Site-Directed 
Mutagenesis Kit (Stratagene).  Primer sequences used for site-directed mutagenesis for 
each family are provided in the Supplementary Appendix. 
 
Construct sequences were confirmed by sequencing in both directions.  Since the pCMV-
Sport6 vector contains Gateway cloning (Invitrogen) recombination sites, we used this 
cloning strategy to insert normal and mutated CD73 cDNA into the vector pLenti6.3/V5-
DEST; lentivirus was generated with the use of the ViraPower HiPerform Lentiviral 
Gateway Expression Kit (Invitrogen).  For transduction, viral particles were added to 
cells in growth medium containing 6 µg of polybrene per milliliter (Sigma).  To select for 
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cells transduced with virus, blasticidin (Invitrogen; 10 µg per milliliter) was added to 
growth medium 4 days after transduction. 
 
Transfection into HEK293 cells 
HEK293 cells (from human embryonic kidneys) were cultured in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal-calf serum and 1% penicillin–
streptomycin.  One microgram of pCMV-Sport6 containing green fluorescent protein, 
wild-type NT5E cDNA, or mutated NT5E cDNA was transfected into HEK293 cells with 
the use of FuGENE 6 reagent (Roche) according to the manufacturer’s instructions.  
Three days after transfection, cells were analyzed for CD73 activity, as described above. 
 
In vitro alkaline phosphatase and calcium assays 
Staining for alkaline phosphatase was performed by means of the Alkaline Phosphatase 
Detection Kit (Millipore).  Assay of alkaline phosphatase was performed with the use of 
the Quantitative Alkaline Phosphatase ES Characterization Kit (Millipore) according to 
the manufacturer’s instructions.  Briefly, cells were trypsinized and collected in aliquots 
of 60,000 cells per reaction in p-nitrophenol–phosphate substrate.  Alkaline phosphatase 
was quantified by measuring the amount of p-nitrophenol produced, as gauged by 
absorption at 405 nm. 
 
A modified protocol for in vitro calcification was used for fibroblasts obtained from 
patients and controls
292,293
.  Cultures were treated with 0.1 µM dexamethasone, 50 µM 
ascorbic acid-2-phosphate, and 10 mM β-glycerol phosphate in alpha minimal essential 
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medium supplemented with 10% fetal-calf serum and 1% penicillin–streptomycin for 21 
days, with replenishment of the medium every 4 or 5 days.  On day 21, cells were washed 
with phosphate-buffered saline and fixed in 10% formalin for 10 minutes.  After washing 

























TREATMENT OF HYPOPHOSPHATEMIC RICKETS IN GENERALIZED 
ARTERIAL CALCIFICATION OF INFANCY (GACI) WITHOUT WORSENING 
OF VASCULAR CALCIFICATION 
 
I. ABSTRACT 
Patients with GACI develop vascular calcifications early in life.  About half of them die 
within the first six months despite optimal medical care.  A subset of those who survive 
eventually develop hypophosphatemic rickets.  Since hypophosphatemia and 
hyperphosphaturia have been previously associated with increased survival in GACI 
patients, physicians often avoid Pi repletion as treatment for rickets.  As a consequence, 
GACI patients develop severe rachitic complications such as short stature and skeletal 
deformities.  It appears that the recognition of hypophosphatemia later in life in some 
GACI patients is a consequence of having survived the first few months of life, and not 
the cause of their survival per se.  Here, we report the long-term follow-up of a GACI 
patient who was Pi-repleted for his rickets for more than seven years without worsening 
of vascular calcification. 
 
II. INTRODUCTION 
GACI is a disorder characterized by calcifications of large- to medium-sized vessels 
and/or fibrointimal hyperplasia resulting in cardiovascular morbidity either in utero or 
soon after birth
3
.  Most cases are associated with biallelic loss-of-function mutations in 
the ENPP1 gene
4





.  A retrospective study of 55 patients with GACI found that 
hypophosphatemia and hyperphosphaturia were associated with increased survival
4
.  
However, the same study found that mortality was largely limited to the so called 
“critical period” encompassing the first six months of life, with only one death occurring 
later, at seven months of age.  Moreover, hypophosphatemia and hyperphosphaturia did 
not develop until later in life, so it is unlikely that these Pi abnormalities themselves 
influenced survival.  Later publications found that ENPP1 mutations are also associated 
with autosomal recessive hypophosphatemic rickets type 2 (ARHR2)
295,296
, so it is not 
surprising that many patients with ENPP1-associated GACI who survive the critical 
period go on to develop rickets.  Thus, the development of hypophosphatemia and 
hyperphosphaturia represent an acquired — rather than a congenital — biochemical 
phenotype that does not appear until after the critical period of increased mortality in 
infancy.  We are aware of several GACI patients who developed hypophosphatemic 
rickets that went untreated for years for fear that calcitriol and phosphorus 
supplementation would worsen the vascular calcifications, based on the previously 
reported association of hypophosphatemia with increased survival.  These patients went 
on to develop profound skeletal deformities.  In contrast, we now report a patient with 
GACI and subsequent hypophosphatemic rickets who was treated with calcitriol and 
phosphorus for more than seven years, without developing new calcium deposits.  This 
demonstrates that hypophosphatemic rickets in the setting of pre-existing GACI can be 
treated without detrimental effects; in fact, such therapy appears appropriate to prevent 




III. CLINICAL REPORT 
Our patient was born at 38 weeks of gestation by spontaneous vaginal delivery after an 
unremarkable prenatal course.  Birth weight was 3.4 kg (25-50
th
 centile) and birth length 
48.9 cm (~25
th
 centile); Apgar scores were 9 and 10 at 1 and 5 minutes, respectively.  At 
day 29, he became cyanotic; in the emergency department, he was in severe respiratory 
distress, with mottled skin and metabolic acidosis.  He was placed on a ventilator and on 
vasopressors, but was breathing room air on his own two days later, and was discharged 
home on an apnea monitor five days later.  On day 48, the infant began crying 
inconsolably.  In the emergency department, he was tachycardic with poor peripheral 
perfusion, hepatomegaly and splenomegaly.  A chest radiograph revealed cardiomegaly 
and pulmonary edema, and an EKG showed left ventricular hypertrophy.  An 
echocardiogram showed left ventricular enlargement, poor systolic function, and 
moderate mitral regurgitation.  A myocardial biopsy was unremarkable, with no findings 
of myocarditis.  Cardiac catheterization showed severe attenuation of the left coronary 
artery with subtotal occlusion of the first obtuse marginal branch and occlusion proximal 
to the circumflex branch.  The right coronary artery was occluded proximally.  A CT scan 
revealed calcification of the descending aorta, and the renal, splenic, superior mesenteric, 
brachial and coronary arteries, consistent with the diagnosis of GACI.  Biallelic 
mutations in ENPP1 (p.Arg481Gln and p.Tyr471Cys; NM_006208.2) confirmed the 
diagnosis.  During that hospital admission, he was started on etidronate IV for 7 days and 
then orally at 20 mg/kg/day.  During the hospitalization, the echocardiogram improved 
dramatically, with the left ventricular shortening fraction increasing from 13% on 




CT at 7 months of age showed reduced calcifications, and by 13 months the calcifications 
had regressed completely except for mild calcification of the aortic annulus.  Etidronate 
was discontinued at 24 months of age.  
 
At 13 years of age, the patient began complaining of significant, progressive pain in the 
ankles and knees, accompanied by stiffness of both joints, mainly in the morning.  
Radiographs revealed significant anterior bowing and thinning of the lower ends of both 
femora.  A skeletal survey at 14 years 5 months showed resorption of the proximal 
medial metaphyses of both tibias and widening of the growth plates of the distal ulnae 
bilaterally and, to a lesser extent, the medial margins of the distal radius.  Fusion of the 
posterior arches of C2, C3, C4 and C5 was also found. 
 
At 14 years 5 months, his height was 154.4 cm (7
th
 centile, -1.45 SD) for a mid-parental 
height of 180.3 cm ± 5 cm (75
th
 centile).  He was diagnosed with hypophosphatemic 
rickets, based on an elevated alkaline phosphatase of 631 U/L (reference: 166-571 U/L), 
bone specific alkaline phosphatase 241 μg/L (ref: 13-111 μg/L), serum phosphorus 2.5 
mg/dL (ref: 3.5-5.3 mg/dL), tubular reabsorption of phosphorus (TRP) 88 % (low for his 
degree of hypophosphatemia), tubular maximum phosphorus reabsorption per glomerular 
filtration rate (TmP/GFR, or threshold above which phosphorus is no longer reabsorbed 
by the tubules) 2.3 mg/dL (ref: 2.8-5.2 mg/dL), intact PTH 39 pg/mL (ref: 15-65 pg/mL), 
25-hydroxyvitamin D 35 ng/mL (ref: 30-50 ng/mL) and 1,25-dihydroxyvitamin D 36 
pg/mL (ref: 24-86 pg/mL).  Phosphorus supplementation was initiated with K-Phos 
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Neutral at 250 mg every 6 hours (18 mg/kg/d), and calcitriol was begun at 0.5 μg twice a 
day (18 ng/kg/d) starting at 14 years 8 months of age. 
 
Within a few weeks of starting therapy, the pain in his ankles and knees resolved 
completely.  His deformities remained stable, with no progression or improvement.  After 
his final height was achieved, he underwent two separate osteotomies at age 21 to correct 
the anterior femoral bowing with tibia vara.  
 
Other pertinent medical findings included progressive hearing loss noted at age 7 years, 
for which he had PE tubes until the age of 20 years, followed by hearing aids.  He also 
had enamel defects, requiring sealant application.  
 
At the age of 21 years 11 months, the patient was taking calcitriol 0.75 μg every morning 
and 0.5 μg nightly (13.9 ng/kg/d) and phosphorus 500 mg twice a day (11.1 mg/kg/d).  
Dose adjustments were made based on blood and urine biochemical findings, although 
with some medication adherence issues.  His ionized calcium was 1.23 mmol/L (ref: 1.1-
1.35 mmol/L), serum phosphorus 2.1 mg/dL (ref: 2.5-4.5 mg/dL), alkaline phosphatase 
191 U/L (ref: 45-115 U/L), and intact PTH 11 pg/mL (ref: 15-65 pg/mL).  Multidetector 
helical CT from the neck to the legs revealed minimal calcification of the aortic root (Fig. 
15A) and inferior portion of the heart, and minimal calcification of the left popliteal 
artery, with no calcifications elsewhere (including no nephrocalcinosis).  Anterior 
femoral bowing could also be appreciated (Fig. 15B).  A dedicated cardiac CT showed no 




Fig. 15. Imaging of patient with GACI.  (A) CT revealed minimal calcification in the 









In 2008, Rutsch et al. reported the association of hypophosphatemia and 
hyperphosphaturia with increased survival in patients with GACI
6
. Association, however, 
does not imply causality, and in fact this association was based upon the finding that 
GACI patients who survived beyond infancy were hypophosphatemic and 
hyperphosphaturic.  The 2008 report did not address the fact that the GACI patients who 
died during their first year of life might also have been destined to develop renal Pi 
wasting and hypophosphatemia later in life.  Furthermore, there was no mortality in 
either patients with or without hypophosphatemia/hyperphosphaturia after 7.5 months of 
age, meaning that there is no evidence for a causal relationship between survival and 
hypophosphatemia after early infancy.  Thus, the biochemical phenotype of 
hypophosphatemia and hyperphosphaturia will likely develop over time in many patients 
with GACI who survive the critical period, but it is not an explanation for survival.  
Rather, survival itself allows hypophosphatemia to be recognized; hypophosphatemia 
does not lead to survival. 
 
There are various explanations why a “critical period” in the first six months of life might 
be followed by a more “refractory period” later.  First, in most cases the calcifications 
regress either spontaneously
297,298
 or after treatment with bisphosphonates
299,300
.  Second, 
even though patients with GACI can have vessel narrowing in the presence or absence of 
calcifications, the authors are aware of several patients who received serial imaging 
showing that their vessels continued to grow in diameter with age.  According to 





.  Thus, a linear increase in the caliber of a vessel will lead to an exponential 
increase in blood flow, so that small increases in the radius can lead to dramatic increases 
in flow. 
 
Based upon the reported association of hypophosphatemia and hyperphosphaturia with 
increased survival, many physicians avoid treating the rickets that develop in children 
and young adults with GACI.  Yet it is well known that these patients can have ENPP1-
mediated hyperphosphaturia and hypophosphatemia and go on to develop florid rachitic 
deformities.  Clearly, the decision to start therapy is difficult, since the effects of long-
term calcitriol and phosphorus supplementation in GACI patients remain unknown.  
However, it should be noted that GACI is hypothesized to be caused by a cell-
autonomous defect, leading to increased vascular calcification presumably due to lack of 
PPi synthesis in the local microenvironment of the vessel wall.  Indeed, newborn patients 
with extensive vascular calcifications have normal phosphatemia and calcemia 
suggesting that vascular calcification does not appear to be related to any abnormalities in 
circulating levels of Pi or calcium.  
 
Moreover, there is one report of a patient with biallelic ENPP1 mutations who, after 
initiation of alfacalcidol, developed new-onset nephrocalcinosis, cardiac, hepatic and 
pancreatic calcifications as evaluated by ultrasound, and recurrence of previously 
regressed periarticular calcifications as assessed by radiograph
13
.  This, however, was an 
iatrogenic event, since the patient developed hypercalciuria during treatment, and once 
the calciuria was maintained at less than 4 mg/kg/day, most of these calcifications — 
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with the exception of nephrocalcinosis — regressed.  In another report, Rutsch et al. 
found one GACI patient treated with calcitriol and phosphorus supplementation whose 
arterial stenosis worsened
6
.  However, no clinical information was provided regarding the 
timing of institution of treatment in this patient, the degree of vascular calcification prior 
to treatment initiation, the dosage of the supplemented medications, or the possibility of 
iatrogenic adverse effects such as hypercalciuria.  
 
In conclusion, we describe for the first time long-term treatment of hyphosphatemic 
rickets in the setting of GACI.  We show that adequate treatment of rickets can be 
accomplished without worsening of vascular calcifications, as long as close monitoring is 















 CHAPTER 4 
ECTOPIC CALCIFICATION IN PXE REFLECTS COMPLEX ATP 
METABOLISM DEFECTS AND RESPONDS TO TNAP INHIBITION 
 
I. ABSTRACT 
Biallelic mutations in ABCC6 cause PXE, a disease characterized by calcification in the 
skin, eyes, and blood vessels.  The function of ABCC6 and the pathogenesis of PXE 
remain unclear.  We used mouse models and patient fibroblasts to demonstrate genetic 
interaction and shared biochemical and cellular mechanisms underlying ectopic 
calcification in PXE and related disorders caused by defined perturbations in extracellular 
ATP catabolism.  Under osteogenic culture conditions, ABCC6 mutant cells calcified, 
suggesting a provoked cell-autonomous defect.  Using a conditional Abcc6 knockout 
mouse model, we excluded the prevailing pathogenic hypothesis that singularly invokes 
failure of hepatic secretion of an endocrine inhibitor of calcification.  Instead, deficiency 
of Abcc6 in both local and distant cells was necessary to achieve the early onset and 
penetrant ectopic calcification observed upon constitutive gene targeting.  ABCC6
 
mutant 
cells additionally had increased expression and activity of TNAP, an enzyme that 
degrades PPi, a major inhibitor of calcification.  A novel, selective, and orally 
bioavailable TNAP inhibitor prevented calcification in ABCC6
 
mutant cells in vitro and 
attenuated both the development and progression of calcification in Abcc6
-/-
 mice in vivo, 






Three human diseases, GACI, CALJA, and PXE, are characterized by debilitating ectopic 
calcification.  The current understanding of the pathogenesis of GACI and CALJA 
suggests that aberrations in the extracellular ATP catabolic pathway cause ectopic 
calcification; it is unclear if a similar mechanism also applies to PXE.  GACI (OMIM 
#20800), the most serious of these disorders, often presents by three months of age with 
myocardial infarction secondary to occlusive coronary artery calcification
4
.  Patients also 
have extensive medial calcification of their medium-sized and large arteries, predisposing 
to strokes, and heart failure
3
.  GACI generally results from biallelic loss-of-function 
mutations in ENPP1, which encodes an extracellular ectonucleotide 
pyrophosphatase/phosphodiesterase that converts ATP into AMP and PPi
4
, a potent 
inhibitor of calcification in vitro
302
 and in vivo
8
.  Loss of ENPP1 activity results in 





 PPi levels.   
 
CALJA (OMIM #211800) is an adult-onset disorder of medial arterial and joint 
calcification.  Patients typically present in their third decade of life with lower extremity 
claudication due to calcification of the femoral, popliteal, and dorsalis pedis arteries, in 
addition to extra-articular joint calcification.  CALJA is caused by biallelic loss-of-
function mutations in NT5E, which encodes CD73, an ecto-5’-nucleotidase that 
participates in ATP metabolism by degrading AMP to adenosine and Pi
20
.  While 
calcification in GACI appears directly related to PPi deficiency, dysfunctional CD73 has 
been linked to increased PPi degradation by TNAP.  Increased TNAP activity in CALJA 
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is believed to be secondary to reduced levels of extracellular adenosine and consequent 
impairment of intracellular adenosine receptor signaling that inhibits TNAP expression
20
.  
Thus, in both GACI and CALJA, ectopic calcification appears to be related to reduced 
extracellular concentration of the calcification inhibitor PPi.  
 
In contrast to our understanding of GACI and CALJA, the mechanism of PXE (OMIM 
#264800), an autosomal recessive disorder of elastic fiber calcification, remains largely 
unknown.  PXE patients exhibit calcification of elastic fibers in the skin, eyes, and 
arterial wall, resulting in characteristic papular lesions and skin laxity at flexure regions, 
fragmentation of Bruch’s membrane underlying the retina leading to central vision loss, 
and medial arterial calcification causing peripheral vascular insufficiency.  PXE typically 
results from mutations in ABCC6, which encodes a presumptive ATP-dependent 
exporter
303,304
.  Remarkably, rare patients with biallelic mutations in ABCC6 develop 





The function of ABCC6 remains unclear.  ABCC6 is a member of the multidrug 
resistance protein family with demonstrated transporter activity
240
, but its endogenous 
substrate is unknown.  The ABCC6 protein has very low expression in the peripheral 
cells directly affected in PXE, i.e., dermal fibroblasts and vascular smooth muscle 
cells
241,242
, but strong expression in the liver and, to a lesser extent, kidney.  The 
prevailing mechanistic hypothesis suggests that hepatocellular ABCC6 exports an 
endocrine inhibitor of calcification that acts at distant target sites
243–245,250
 and that failure 
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of this event is sufficient to cause the systemic manifestations of PXE; only 
circumstantial evidence exists for this pathogenic model.  Lack of understanding of 
disease pathogenesis has resulted in limited treatment options for PXE.  Here, we attempt 
to unravel the mechanisms underlying PXE to better understand the pathways involved in 
ectopic calcification and conceive new therapeutic approaches. 
 
III. RESULTS 
Crossing Abcc6 to Enpp1 and Nt5e mutant mice reveals genetic interaction. 
Because of the observed locus heterogeneity within the cohort of patients manifesting 
GACI and the clinical overlap among PXE, GACI, and CALJA, our initial hypothesis 
was that ABCC6 functions within the extracellular ATP metabolism pathway.  To test 
this, we generated all possible genetic allele combinations by crossing Abcc6 mutant 
mice to Enpp1 or Nt5e deficient mice.  Micro-computerized tomography (micro-CT) was 
used to quantify the extent of calcification of the fibrous capsule surrounding the mouse 
vibrissae (whiskers on the muzzle; Fig. 16), an early marker of ectopic calcification
145
.  
By 15 weeks of age, Abcc6
-/- 
mice showed only moderate calcification whereas Abcc6
-/- 
mice with one mutated Enpp1 allele showed worsening of the phenotype (Fig. 17A, B).  
Enpp1
-/-
 mice showed very aggressive calcification, with no further accentuation upon 
deleting Abcc6 alleles.  There was significant interaction between Abcc6 and Enpp1 (two-
way analysis of variance, Abcc6 effect: P=2.2x10
-16
, Enpp1 effect: P=2.2x10
-16
, 
interaction effect: P=2.2 x10
-16
).  The fact that the calcification phenotype is saturated 
upon full loss of Enpp1 function, with no added effect of targeting Abcc6 alleles, is 











Fig. 16. Location of calcification in the fibrous capsule surrounding the vibrissae.  












Crosses between Abcc6 and Nt5e deficient mice also revealed evidence for genetic 
interaction (Fig. 17C, D).  By 15 weeks of age, Nt5e
-/-
 mice with or without one null 
Abcc6 allele showed no evidence of calcification and deleting one Nt5e allele in Abcc6
-/- 
mice did not exacerbate calcification.  However, Nt5e
-/-
 mice with two null Abcc6 alleles 
showed calcification that was more severe than that observed in Abcc6
-/-
 mice.  This 
interaction was statistically significant (two-way analysis of variance, Abcc6 effect: 
P=2.2x10
-16
, Nt5e effect: P=1.2x10
-4
, interaction effect: P=1.1x10
-3
).  When aged to one 
year, Nt5e
-/- 
mice showed mild calcification that was exacerbated by homozygous loss of 
Abcc6, again documenting genetic interaction (Fig. 18A, B; two-way analysis of 
variance, Abcc6 effect: P=2.2x10
-16
, Nt5e effect: P=1.7x10
-13
, interaction effect: 
P=5.8x10
-7
).  In this set of crosses, the observation that maximal phenotypic severity is 
only observed upon complete loss of function for both Abcc6 and Nt5e suggests that they 
work in combination rather than in tandem.  Taken together, these findings suggest that 
PXE is caused by defects in the same pathway as GACI and CALJA; a parsimonious 
model places ABCC6 acting downstream of ENPP1 and in parallel with CD73, but more 
complex scenarios cannot be excluded. 
 
Fibroblasts cultured from patients with biallelic ABCC6 mutations can calcify in 
vitro and have altered levels of enzymes in the extracellular ATP catabolic pathway.  
To further probe whether metabolic defects observed in GACI and CALJA might also 
underlie the calcification phenotype in PXE, we generated primary fibroblast cell lines 





), or NT5E (NT5E
Mut/Mut




Fig. 17. Crossing Abcc6 to Enpp1 or Nt5e mutant mice reveals genetic interaction.  
Abcc6 mutant mice were crossed to Enpp1 or Nt5e mutant mice to generate all possible 
genetic allele combinations.  (A, C) Micro-CT scans of the muzzle to evaluate the extent 
of vibrissae fibrous capsule calcification were obtained at 15 weeks of age.  
Representative coronal z-stacked images of the mouse muzzle with the nasal bones and 
sinuses midline (indicated by white asterisk) and the pathological calcification seen as 
radiodense lesions (indicated by yellow arrow) in the surrounding soft tissue.  (B, D) 
Quantification of ectopic calcification from micro-CT images.  A two-way analysis of 
variance with a Tukey’s honest significance difference post-hoc analysis was performed; 







Fig. 18. Demonstration of genetic interaction between Abcc6 and Nt5e mice when 
aged to one year.  (A) Micro-CT scans of the muzzle to evaluate the extent of vibrissae 
fibrous capsule calcification were obtained at one year of age.  (B) Quantification of 
ectopic calcification from micro-CT images.  A two-way analysis of variance with a 









mutations were missense, nonsense, frameshift, or deletions (Table 2).  In contrast to 
control fibroblasts ABCC6
Mut/Mut
 cell lines, when cultured to confluency and then 
stimulated with osteogenic media for 21 days, exhibited fully penetrant but variably 
severe calcification, as assessed by Alizarin red staining (Fig. 19A, B; one-tailed 
Student’s t-test: P=0.045).  As previously reported, the same stimulation with osteogenic 







These data demonstrate a cell-autonomous predisposition in ABCC6
Mut/Mut
 cells that 
requires exogenous provocation for phenotypic expression and validate the use of these 
cells for further biochemical analysis of the functional consequences of ABCC6 
mutations in vitro. 
 
We measured the steady-state enzymatic activity levels of ENPP1 and CD73, and their 







 fibroblasts.  As expected, ENPP1
 Mut/Mut





 cells had increased ENPP1 enzymatic activity compared to 
controls (Fig. 19C; one-way analysis of variance: P=0.001).  Additionally, there was a 
marked increase in ENPP1 mRNA expression in ABCC6
Mut/Mut
 cells compared to controls 
(Fig. 19D; one-way analysis of variance: P=0.016).  ENPP1 mRNA expression was also 
elevated in ENPP1
Mut/Mut
  cells (all containing at least one missense allele), but the 
mutated protein lacked function, as predicted.  These data are consistent with the ordered 
biochemical pathway inferred from our genetic interaction data and suggest that 
mutations in genes encoding for proteins distal to ENPP1 lead to compensatory 




Table 2. List of patient mutations in ABCC6 (NM_001171.5), ENPP1 (NM_006208.2), 











is impossible with biallelic loss-of-function mutations in ENPP1, perhaps reconciling the 









 cells exhibited decreased CD73 activity compared to 
controls (Fig. 19E; one-way analysis of variance: P=3.51x10
-5





 cells were similar to those in control cells but 
decreased in  NT5E
Mut/Mut
 cell lines, all of which have biallelic mutations creating a 
premature termination codon expected to elicit nonsense-mediated mRNA decay (Fig. 
19F; one-way analysis of variance: P=0.038).   These data suggest that reduced 
production and/or bioavailability of substrate (i.e., AMP) limits CD73 activity, but not 
expression.  This demonstration of metabolic crosstalk among ENPP1, CD73, and 
ABCC6 further validates the conclusion that ABCC6 contributes to extracellular ATP 
metabolism.   
 
Liver-specific deletion of Abcc6 does not fully recapitulate the global Abcc6
-/-
 
phenotype implicating the role of both local and systemic factors in ectopic 
calcification. 
Prior reports demonstrating high expression of ABCC6 in the liver and low expression of 
ABCC6 in disease-affected tissues
241
 have advanced a liver-centric mechanistic 
hypothesis for PXE
243
, i.e., that peripheral tissue calcification reflects failed liver 
secretion of an endocrine inhibitor of calcification.  In contrast, our in vitro findings 




Fig. 19. Evidence for a provoked cell-autonomous defect and alterations in enzymes 
integral to the extracellular catabolism of ATP in ABCC6 mutant cells.  (A) Primary 
dermal fibroblasts derived from patients with biallelic mutations in ABCC6 
(ABCC6
Mut/Mut
) calcify in vitro when stimulated with osteogenic media, as indicated by 
alizarin red staining.  Representative images demonstrating the spectrum of calcification 
are shown.  (B) Quantification of the alizarin red staining was determined by colorimetric 
analysis.  A one-tailed Student’s t-test was performed; P-value indicated.  (C, D, E, F) 
Quantification of enzyme activity and gene expression for ENPP1 (ENPP1) and CD73 
(NT5E) in primary dermal fibroblasts derived from patients with biallelic mutations in 
ABCC6, ENPP1,
 
or NT5E.  A one-way analysis of variance with a Tukey’s honest 





 fibroblasts is sufficient to predispose to calcification, but that an exogenous 
trigger is required for phenotypic expression.  To explore this issue in vivo, we generated 
a mouse carrying a conditional Abcc6 allele (Abcc6
flox/flox
) that was subsequently crossed 
to a number of different lines that express Cre recombinase in a cell type- or tissue-
specific manner.   
 
As evidenced by micro-CT, global ablation of Abcc6 with CMV-Cre resulted in 
calcification of the fibrous capsule surrounding the muzzle vibrissae at 20 weeks of age, 
fully recapitulating the phenotype of Abcc6
-/-
 mice (Fig. 20A, B; one-way analysis of 
variance: P=2.2x10
-16
).  Contrary to the proposed liver-centric model, however, efficient 




Alb-Cre) failed to 
induce any calcification at 20 weeks (Fig. 20A, B).  We verified efficient deletion of 
Abcc6 in hepatocytes by breeding the Alb-Cre mice to a Rosa
mTmG 
mouse line; all cells 
that recombine change expression from membrane Tomato (mT; red fluorescence) to 




Alb-Cre mice showed green fluorescence (Fig. 20C). 
 
Cell-type or tissue-specific ablation of Abcc6 using Cre drivers specific for vascular 
smooth muscle (SM22α-Cre), vascular endothelium (VE-Cadherin-Cre), skeletal muscle 
(Pax7-Cre), renal tubular cells (Cdh16-Cre), pericytes (Pdgfrβ-Cre), adipocytes (Fabp4-
Cre), and bone marrow (CD45-Cre), also failed to induce calcification at 20 weeks of age 
(Table 3).  Curiously, one of 22 mice with Wnt1-Cre mediated ablation of Abcc6 in the 




Fig. 20. Liver-specific deletion of Abcc6 does not phenocopy constitutive ablation of 
Abcc6.  Micro-CT scans of the muzzle to evaluate the extent of vibrissae fibrous capsule 
calcification were obtained at 20 weeks of age (A) and 1 year (D).  (B, E) Quantification 
of ectopic calcification from micro-CT images.  A one-way analysis of variance with a 
Tukey’s honest significance difference post-hoc analysis was performed; P-values 
indicated.  (C) Visualization and confirmation of Cre-targeted tissues and cell types 
utilizing the Rosa
mTmG 
reporter mouse line.  All cells which are successfully recombined 
transition from expression of membrane Tomato (mT; red fluorescence) to green 
fluorescent protein (mG; green fluorescence).  Representative images shown.   
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the fibrous capsule at 20 weeks of age (Fig. 20A, B; Table 3).  Upon breeding the Wnt1-
Cre mouse line to a Rosa
mTmG 
reporter, we discovered mosaic recombination within the 
liver; at 20 weeks of age, green fluorescence (indicating recombination) was observed in 
approximately 12% of hepatocytes (Fig. 20C).   
 








Wnt1-Cre mice showed 
reduced penetrance and variable expressivity of calcification of the vibrissae fibrous 




CMV-Cre mice (Fig. 20D, E; table S2; one-way 
analysis of variance: P=4.68x10
-11
).  Deleting Abcc6 in all other cell types and tissues 
tested did not result in calcification at one year of age (Table 3).  These data suggest that 
the loss of Abcc6 expression in the liver sensitizes to calcification, but that this event in 
isolation is insufficient to achieve the threshold loss-of-function needed for highly 
penetrant and severe phenotypic expression.  The efficiency of the tissue-specific Abcc6 







CMV-Cre mice had no measureable expression of Abcc6 in the liver 
or kidney when compared to normal levels in control mice (Fig. 21A; one-way analysis 
of variance: P=2.2x10
-16







Alb-Cre mice had no Abcc6 expression in the liver (Fig. 21A), though 




Wnt1-Cre mice had a 
substantial (five-fold), yet incomplete, reduction of Abcc6 expression in the liver (Fig. 





























Fig. 21. Demonstration of efficient liver-specific deletion of Abcc6 in mice.  
Expression of Abcc6 in the liver (A) and kidney (B) of control, Abcc6
-/-
, and Cre-targeted 
Abcc6
flox/flox
 mice.  A one-way analysis of variance with a Tukey’s honest significance 






Next, we deleted Abcc6 in a combinatorial manner in an attempt to recapitulate the robust 






CMV-Cre mice.  Deleting 





including the liver and kidney, did not result in calcification at 20 weeks of age, 
providing strong evidence against a pathogenic hypothesis that singularly invokes an 
endocrine mechanism (Fig. 22A, B).  Knocking out Abcc6 in the liver and all skeletal 





also did not induce calcification.  Interestingly, targeting Abcc6 in the liver and in Wnt1-





Alb-Cre; Wnt1-Cre), induced calcification at 20 weeks, albeit with reduced 
penetrance (5 of 13 mice calcified).  All Cre-line combinations were also bred to a 
Rosa
mTmG 
mouse line to confirm efficient targeting of the cell and/or tissue type (Fig. 
22C).   
 
Although circulating PPi levels appear decreased in Abcc6
-/- 
mice and PXE patients
252
, it 
remains uncertain whether decreased plasma PPi is the primary determinant of disease.  
To explore if deleting Abcc6 in a combinatorial method was further decreasing 
circulating PPi levels in an additive manner that correlated with the severity of ectopic 
calcification, we measured plasma PPi levels in different cell- and tissue-specific Abcc6 
knockout mouse models at one year of age and simultaneously quantified vibrissae 





CMV-Cre) resulted in a robust calcification phenotype (Fig. 23A, 
B; one-way analysis of variance: P=1.09x10
-5




Fig. 22. Evidence that both local and systemic defects in ATP metabolism are 
needed to promote PXE-associated ectopic calcification.  (A) Micro-CT scans of the 
muzzle demonstrating ectopic calcification at 20 weeks of age upon deletion of Abcc6 in 
both the liver and local Wnt1-positive cells in the fibrous capsule, albeit with reduced 
penetrance compared to constitutive targeting (Fig. 3A, B).  (B) Quantification of ectopic 
calcification from micro-CT images.  A one-way analysis of variance with a Tukey’s 
honest significance difference post-hoc analysis was performed; P-values indicated.  (C) 
Visualization and confirmation of Cre-targeted tissues and cell types utilizing the 
Rosa
mTmG 
reporter mouse line.  Representative images shown.   
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significantly below those observed in control animals (Abcc6
flox/flox
) (Fig. 23C; one-way 








Alb-Cre; Cdx1-Cre) exhibited much milder vibrissae 




CMV-Cre mice (Fig. 23A, B), and yet 
showed comparably reduced levels of circulating PPi (Fig. 23C).  The same knockout 





mice despite normal circulating PPi levels in the latter.  These data document poor 
correlation between the severity of calcification and the level of circulating PPi.    
 
Of all the cell-type or tissue-specific Cre drivers utilized in this study, only use of Wnt1-
Cre was associated with recombination within the fibrous capsule of the vibrissae (Fig. 









Alb-Cre animals cannot plausibly relate to enhanced 
liver recombination.  Taken together, these data suggest cooperation between local and 
systemic events in the initiation of calcification in PXE. 
 
TNAP inhibition prevents in vitro calcification in cell lines with biallelic ABCC6 
mutations under osteogenic conditions. 
With evidence that local cells contribute to PXE pathogenesis, ABCC6
Mut/Mut
 patient 
fibroblasts emerged as a viable model for investigating potential therapies.  We explored 
whether the calcification was related to increased TNAP levels, since it is known that 
TNAP is a major regulator of in vitro
305
 and in vivo calcification
160,306,307
.  When 
stimulated with osteogenic media for five days, ABCC6
Mut/Mut




Fig. 23. Circulating PPi levels do not correlate with severity of calcification 
phenotype.  (A) Micro-CT scans of the muzzle to evaluate the extent of vibrissae fibrous 
capsule calcification were obtained at one year of age.  (B) Quantification of ectopic 
calcification from micro-CT images.  (C) Quantification of plasma PPi levels. (B, C) A 
one-way analysis of variance with a Tukey’s honest significance difference post-hoc 






enzymatic activity compared to controls (Fig. 24A; two-way analysis of variance, 
genotype effect: P=0.010, treatment effect: P=0.0029, interaction effect: P=0.039).  
Expression of ALPL, the gene encoding TNAP, was concordantly increased (Fig. 24B; 
two-way analysis of variance, genotype effect: P=0.012, treatment effect: P=0.048, 
interaction effect: P=0.18).   
 
Arylsulfonamides are potent and selective inhibitors of TNAP
313
.  SBI-425, an 
arylsulfonamide derivative with optimized pharmacokinetic properties, effectively 
inhibits TNAP in vivo
160
.  Treatment of ABCC6
Mut/Mut
 cells under osteogenic conditions 
with SBI-425 prevented in vitro calcification, whereas mutant cells treated with vehicle 
proceeded to calcify (Fig. 24C, D; two-way analysis of variance, genotype effect: 
P=0.029, treatment effect: P=0.028, interaction effect: P=0.029).  These data demonstrate 
that in vitro calcification of ABCC6
Mut/Mut
 cells is TNAP-dependent, suggesting a 
potential therapeutic target for PXE. 
 
TNAP inhibition attenuates both the development and progression of calcification in 
a PXE mouse model. 
Our demonstration of excessive TNAP levels and activity in ABCC6
Mut/Mut
 cells prompted 
a treatment trial in six week old Abcc6
-/-
 mice with the TNAP inhibitor SBI-425 (30 
mg/kg/day), etidronate (240 mg/kg/day), or control food for 14 weeks.  Micro-CT scans 
at 20 weeks of age revealed significant and equivalent attenuation of the calcification 
phenotype in both SBI-425 and etidronate-treated Abcc6
-/- 
mice (Fig. 25A, B; two-way 
analysis of variance, genotype effect: P=1.2x10
-12







Fig. 24. Primary dermal fibroblasts derived from patients with biallelic mutations in 
ABCC6 show TNAP-dependent in vitro calcification.  (A, B) TNAP enzyme activity 
and gene (ALPL) expression in control and ABCC6
Mut/Mut
 fibroblasts with and without 
osteogenic stimulation.  (C, D) Calcification of ABCC6
Mut/Mut
 fibroblasts is abrogated 
upon treatment with the TNAP inhibitor, SBI-425.  (A, B, D) A two-way analysis of 








).  Mice were treated before the onset of any sign of 
calcification, as evidenced by micro-CT at six weeks of age, although microscopic nidi of 
calcification cannot be excluded.  The therapeutic effect of both SBI-425 and etidronate 
was substantiated by measuring the calcium phosphate precipitate in muzzle tissue (Fig. 
25C; one-way analysis of variance: P=8.4x10
-4
).  Serum samples taken from treated mice 
demonstrated that SBI-425 robustly inhibited plasma TNAP activity, whereas etidronate 
and control treatments did not, as expected (Fig. 25D).  Since there was no effect of 
genotype (two-way analysis of variance, genotype effect: P=0.64, treatment effect: 
P=8.7x10
-12
, interaction effect: P=0.92), genotype was collapsed to evaluate for 
differences across treatment groups (one-way analysis of variance: P=1.5x10
-13
).  While 
Abcc6
-/-
 mice had decreased circulating PPi levels compared to control mice, SBI-425 did 
not significantly increase PPi levels, potentially highlighting the contribution of local 
events to the pathogenesis of PXE (Fig. 26; two-way analysis of variance, genotype 
effect: P=0.0017, treatment effect: P=0.24, interaction effect: P=0.72). 
 
Femora were evaluated for bone microarchitecture, mineralization, and mechanical 
properties at the conclusion of the treatment trial.  Imaging of the femora showed 
significant effects of sex and treatment, but not genotype, across all trabecular bone 
parameters.  It has been well-established that trabecular architecture differs between male 
and female C57BL/6 mice, in an age-related manner, starting between two and six 
months of age
308
.  SBI-425 treatment did not result in any changes to bone 
microarchitecture.  In contrast, etidronate treatment resulted in increased trabecular bone 






Fig. 25. TNAP inhibition attenuates calcification in a PXE mouse model.  (A, B) 
Micro-CT scans revealed significant attenuation of the calcification phenotype in both 
SBI-425 and etidronate-treated Abcc6
-/- 
mice.  Control mice did not calcify.  A two-way 
analysis of variance with a Tukey’s honest significance difference post-hoc analysis was 
performed; P-values indicated.  (C) Micro-CT results were validated by dissolving the 
muzzle tissue and quantifying the calcium phosphate precipitate.  (D) Plasma obtained 
from mice at the conclusion of the treatment trial showed that SBI-425 strongly inhibited 
residual TNAP activity levels.  (C, D) A one-way analysis of variance with a Tukey’s 








Fig. 26. TNAP inhibition does not alter circulating PPi levels in mice.  Quantification 
of PPi levels in control and Abcc6
-/-
 mice treated with vehicle or the TNAP inhibitor SBI-
425.  A two-way analysis of variance with a Tukey’s honest significance difference post-












, genotype effect: P=0.49) and increased number of 





, genotype effect: P=0.48), with decreased intertrabecular 





, genotype effect: P=0.77) in the distal femur in both male and female 
mice.  Etidronate-treated male, but not female, mice also had significantly increased 
trabecular thickness compared to vehicle-treated mice (Fig. 27D, E; three-way analysis of 
variance, gender effect: P=7.2x10
-9
, treatment effect: P=0.0050, genotype effect: 
P=0.62).  Trichrome staining of the undecalcified distal femora showed no abnormalities 
of bone mineralization in SBI-425 mice, but increased accumulation of osteoid was 
apparent in etidronate-treated animals, as previously reported (Fig. 27F)
309,310
.  Neither of 
the treatment arms altered the cortical bone of the femoral diaphysis, as quantified by 
micro-CT (Table 4) and mechanical testing (Table 5).   
 
To assess for therapeutic potential of SBI-425 in mice with established calcification, 
Abcc6
-/-
animals were aged to 20 weeks and then treated with either vehicle or SBI-425 
(30 mg/kg/day) for 16 weeks.  While vehicle-treated Abcc6
-/-
 mice showed progressive 
muzzle calcification, SBI-425-treated animals did not (Fig. 28; one-way analysis of 
variance: P=0.050).  These data suggest that while TNAP inhibition does not reverse 
existing calcification in this experimental context, it can prevent progression of the 
phenotype.  The potential for chronic treatment to achieve therapeutic tissue remodeling 





Fig. 27. TNAP inhibition had no negative effects on bone microarchitecture or 
mineralization in a PXE mouse model.  Quantification of trabecular bone volume (A), 
number (B), space (C), and thickness (D) in vehicle-, SBI-425-, and etidronate- treated 
mice.  Since there was no effect of genotype in any of the trabecular bone parameters, 
genotype was collapsed to evaluate for differences across treatment groups within each 
sex with a one-way analysis of variance and a Tukey’s honest significance difference 
post-hoc test; P-values indicated.  Representative images from micro-CT scans (E) and 




Table 4. Cortical bone microarchitecture. Treatment with SBI-425 or etidronate did not 
affect cortical bone microarchitecture.  TMD = total mineral density; BA/TA = bone 




Table 5. Cortical bone strength.  Treatment with SBI-425 or etidronate did not affect 








Fig. 28. TNAP inhibition prevents progression of established calcification in a PXE 
mouse model.  Abcc6
-/-
 mice were aged to 20 weeks and then treated with either vehicle 
or SBI-425 for 16 weeks.  The calcium phosphate precipitate was quantified at the 
specified time point.  A one-way analysis of variance with a Tukey’s honest significance 













IV. DISCUSSION  
In this study, both genetic and metabolic analyses provide compelling evidence that 
ABCC6 acts in concert with ENPP1 and CD73 to regulate extracellular PPi, a major 
physiologic inhibitor of calcification.  This work suggests that ENPP1 is required for 
generation of PPi while ABCC6 and CD73 cooperate downstream to inhibit TNAP 
expression and activity and maintain normal PPi levels (Fig. 29).  This interactive 
network reconciles the pronounced clinical severity of GACI and may provide insight 
into the phenotypic diversity associated with ABCC6 deficiency, ranging from early-
onset GACI to late-onset PXE.  Perturbation of this pathway limits the bioavailability of 
PPi, implying the potential for broad therapeutic relevance of TNAP inhibitors. 
 
We demonstrate that ABCC6
Mut/Mut
 cells have the intrinsic capacity to calcify in vitro and 
have altered activity of enzymes involved in ATP catabolism, specifically, increased 
ENPP1 and TNAP and decreased CD73 enzymatic activities.  Consistent with our 
findings, ABCC6
Mut/Mut
 dermal fibroblasts were previously shown to be morphologically 
and biochemically distinct from controls
246–248
 and to have a tendency for matrix 
mineralization
249
.  Although our data concur with prior studies demonstrating that 
ABCC6
Mut/Mut
 cells have higher gene expression and activity of TNAP
249,311
, we showed 
that ABCC6
Mut/Mut
 cells had increased (rather than decreased) ENPP1 enzymatic activity 
and mRNA levels.  These discrepancies might arise from differences in experimental 
design — we measured ENPP1 enzymatic activity and mRNA after five days in culture 
whereas previous reports assayed after 21 days in culture; compensatory mechanisms 







Fig. 29. Proposed involvement of ABCC6 in extracellular ATP metabolism and the 
suppression of ectopic calcification.  ENPP1 metabolizes ATP into AMP and PPi while 
CD73 further degrades AMP into adenosine and Pi.  Adenosine can bind to its cell 
surface receptor to repress ALPL, the gene encoding TNAP.  TNAP degrades PPi into Pi 
and is a primary distal regulator of PPi, a major negative inhibitor of calcification.  Our 
data suggest that ABCC6 is integral to the extracellular ATP metabolism pathway and 
likely works downstream of ENPP1 and in tandem with CD73 to maintain low TNAP 









It has been proposed that the altered behavior of PXE fibroblasts in culture manifest 
memory for an in vivo imbalance of a circulating factor
250
.  However, there exists 
additional evidence that inherent, cell-autonomous defects are operative in PXE.  For 
example, Abcc6-deficient zebrafish show ectopic calcification in the vicinity of 
osteoblasts that normally express Abcc6
251
.  A reconciling view might invoke a role for 
ABCC6 in determining the level of a circulating factor that regulates calcification and a 
local sensitization to its perturbation.  
 
Prior work had shown that fibroblasts from GACI patients deficient for ENPP1 activity 
can also calcify in vitro, yet overexpression of ENPP1 in some, but not all locations in 
enpp1-deficient zebrafish could attenuate calcification at distant target sites
312
.  Taken 
together, these data are consistent with the concept that while necessary, systemic 
perturbations may not be sufficient to elicit disease in ectopic calcification disorders.  
Such considerations highlight the relative importance of in vivo models to interrogate 
disease pathogenesis. 
 
Uitto and colleagues have postulated that PXE is specifically caused by a defect in liver 
secretion of an endocrine inhibitor of calcification at distant target sites
243,244
.  Indeed, 
parabiosis between Abcc6
-/- 
and control mice showed attenuation of the calcification 
phenotype in the mutant animals, when compared to parabiosis between knockouts
245
.  
However, if PXE is solely driven by a deficiency of a systemic factor that equilibrates in 
the circulation, the wildtype partner in a wildtype-to-Abcc6
-/- 
pairing (established prior to 
the onset of calcification) should show the same phenotype as the knockout mouse; this 
121 
 
was not observed.  Hence, isolated deficiency of a circulating metabolite appears 
insufficient to initiate PXE-associated calcification indicating that another factor, perhaps 
imposed by a local cell, contributes to PXE pathogenesis.  Consistent with this, we found 
that deletion of Abcc6 in both the liver and local cells in the fibrous capsule surrounding 
the vibrissae was required to phenocopy the early onset calcification seen upon 
constitutive gene ablation; the ongoing observation of reduced penetrance heralds 
additional complexity regarding the critical threshold level and spatial distribution of 
ABCC6 function.   
 
The observation of decreased circulating PPi in PXE mice and patients
252
 has led to the 
suggestion that PPi is the protective endocrine factor that is missing in PXE; its 
deficiency in the extracellular space could result from impaired transport of ATP out of 
cells, with consequent reduction in AMP and PPi production from ATP catabolism
252
.  In 
fact, overexpression of ABCC6 in HEK293 cells resulted in increased extracellular 
monophosphates, including AMP, a finding thought most consistent with enhanced ATP 
secretion.  However, while increased extracellular ATP was observed after concomitant 
treatment with an ENPP1 inhibitor, there was also a generalized increase in triphosphates, 
diphosphates, and monophosphates suggesting promiscuous effects in this experimental 
system
252
.  In our studies, there was poor correlation between plasma PPi levels and the 
extent of muzzle calcification in mouse models.  While these data do not exclude a 





Though our data have not revealed the precise function of ABCC6, they provide evidence 
that ABCC6 acts downstream of ENPP1, a view inconsistent with the hypothesis that 
ABCC6 is primarily involved in ATP transport.  In addition, the fact that the classical 
GACI phenotype is more severe than later-onset PXE also suggests that ENPP1 functions 
upstream of ABCC6.  Indeed, if ABCC6 were needed to export ATP for extracellular 
processing by ENPP1, then it would be expected that PXE would routinely have a 
phenotype as severe as, or more severe than, GACI; this is not observed.  Our data are 
consistent with a model in which ATP is degraded, at least in part, by intracellular 
ENPP1 to AMP and PPi, with ABCC6 potentially serving to secrete AMP for subsequent 
extracellular processing by CD73 to adenosine, which is then presumed to act through 
cell-surface adenosine receptors to inhibit TNAP expression (Fig. 29)
20
.  While this 
remains to be formally tested, it is notable that prior reports have described intracellular 
ENPP1 activity and there is no described AMP exporter
172–174
.  In theory, ABCC6 could 
also contribute to secretion of PPi, although this is not directly inferred from the data, and 
there is already an established plasma membrane PPi transporter, ANK
169
.  Finally, the 
model proposed by Jansen and colleagues that ABCC6 acts upstream of ENPP1 and 
transports ATP could be partially consistent with our genetic data if there is an alternative 
but limited source of extracellular ATP
252
.  It remains notable, however, that such a 
model would not reconcile our findings suggesting that ABCC6 and CD73 do not act 
sequentially, but rather show cooperative function.  
 
Because of the elusive pathological mechanism underlying PXE, therapeutic targets have 
been limited.  Oral bisphosphonates, which directly disrupt calcium and phosphate 
123 
 
precipitation and hence deposition, have been proposed as a treatment strategy for 
PXE
155
.  Although the first generation bisphosphonate etidronate (100 µg/kg 





, it effectively attenuated calcification in Abcc6
-/-
 mice when used at a high dose 
(240 mg/kg/day orally)
157
.  Nevertheless, etidronate is currently being tested in the 




 (ClinicalTrials.gov ID NCT01585402).  
One drawback is that etidronate results in detrimental changes to bone microarchitecture 
in mice
157
 and in acquired hypophosphatemia with severe skeletal mineralization defects 
in GACI patients
18
.  Our findings suggest that the TNAP inhibitor SBI-425 does not have 
these side effects.   
 
Demonstration that TNAP inhibition attenuates both the development and progression of 
calcification in both in vitro and in vivo models of PXE helps further establish TNAP as a 
disease mediator and an attractive therapeutic target in calcification disorders including 
PXE, GACI, and CALJA.  This finding might also shed light on disease mechanism.  The 
prevailing view that PXE relates to the liver's inability to secrete ATP predicts that there 
is a profound impairment in the generation of extracellular PPi.  In this scenario, TNAP 
inhibition and consequent prevention of PPi degradation would not be effective.  Here we 
provide both genetic and biochemical studies suggesting a role for ABCC6 distal to the 
degradation of ATP to AMP and PPi by ENPP1.  This offers the first rationale that TNAP 
inhibition would be effective.  Given lack of apparent toxicity, TNAP inhibition might 
also be considered for other disorders of ectopic calcification including common 
124 
 
conditions such as aortic valve calcification
313,314
 and chronic kidney disease-associated 
vascular calcification
17,234
, in which decreased PPi has also been documented.   
 
Despite this progress, a number of limitations should be considered.  First, while our 
study draws attention to the potential importance of local events in PXE pathogenesis, the 
precise nature of microenvironmental alterations remains speculative and the ability to 
robustly monitor relevant metabolites is subject to both practical and technical limitations 
in the absence of specific information regarding the physiologic ABCC6 cargo.  Second, 
this study uses the early onset and highly penetrant vibrissae fibrous capsule calcification 
phenotype as a surrogate for tissue calcification events with relevance to patients with 
PXE such as those in the eye and vasculature.  While there has been no documentation 
that vibrissae fibrous capsule calcification is somehow specialized in this regard, the 
broader relevance of findings made in this context remains assumed and will need to be 
documented.  Finally, as always, observations made using model systems allow the 
generation of hypotheses that will require validation in patients with PXE. 
 
V. MATERIALS AND METHODS 
Study design 
The purpose of this study was to elucidate the pathophysiological mechanisms underlying 
PXE and the function of ABCC6 in an effort to rationally design treatment strategies for 
this rare disease patient population.  In order to explore the functional relationships 
among Abcc6, Enpp1, and Nt5e, we generated double-mutant mice and evaluated fibrous 
capsule vibrissae calcification via micro-CT.  Since we saw strong evidence for genetic 
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interaction, we further explored the role of extracellular ATP metabolism in primary 
fibroblasts derived from PXE, GACI, and CALJA patients.  We found evidence for a 
provoked cell-autonomous defect and tested the relevance of these findings in vivo by 
generating a conditional Abcc6 knockout mouse model.  The ability to recapitulate 
pathogenic events in vitro also allowed us to utilize ABCC6
Mut/Mut
 cell lines to explore 
possible therapeutic targets.  When provoked under osteogenic conditions, ABCC6
Mut/Mut
 
demonstrated TNAP-dependent in vitro calcification.  To extend these findings in vivo, 
we treated our Abcc6
-/-
 mice with a TNAP inhibitor.  Efficacy and potential negative 
effects of therapy were evaluated using micro-CT, quantification of calcium phosphate 
deposition, serum collection, and studies of bone microarchitecture, histology, and 
mechanical strength.   
 
Sample sizes were determined on the basis of statistical considerations and on pilot 
experiments that indicated the number of mice per group needed to generate statistical 
significance.  For human cell lines experiments, our sample size was limited by the 
number of skin biopsy samples we were able to collect from patients with these very rare 
conditions.  Both male and female mice and cell lines obtained from males and females 
were evaluated in this study.  Mice were randomly assigned to treatment groups; sex was 
equally distributed among the groups.  All experiments were performed blind to genotype 
and/or treatment.  No outliers were excluded.  Number of biological replicates in each 





Patients were enrolled in clinical protocol 76-HG-0238, “Natural History of Patients with 
Inborn Errors of Metabolism” (clinicaltrials.gov identifier NCT00369421), approved by 
the NHGRI Institutional Review Board.  Written, informed consent was obtained.   
 
Mice 




) were generously provided by Jouni 
Uitto at Thomas Jefferson University.  Enpp1-ablated mice (Enpp1
asj
/GrsrJ, stock 
number: 012810; termed Enpp1
-/-
) and Nt5e knockout mice (Nt5e
 tm1Lft
/J, stock number: 
018986; termed Nt5e
-/-
) were obtained from The Jackson Laboratory.  The first sign of 
calcification in Abcc6
-/-
 mice is in the fibrous capsule surrounding their vibrissae or 
whiskers on the muzzle
145
.  While there is no human equivalent for this fibrous structure, 
its calcification has been well-established as an early biomarker for vascular calcification 
and can be monitored in vivo with micro-CT
315
.  Therefore, all studies analyzed the 
vibrissae fibrous capsule calcification phenotype at 15 or 20 weeks of age since Abcc6
-/- 
do not develop other signs of calcification without provocation until many months later, 
extending beyond the lifespan of Enpp1
-/- 
mice.  We found that Nt5e
-/-
 mice did not 
develop fibrous capsule vibrissae calcification until one year of age.  Therefore, Abcc6 




 embryonic stem cell lines with conditional potential were purchased 
from the European Conditional Mouse Mutagenesis Program.  Embryonic stem cells 
were injected into an albino C57BL/6 blastocyst (B6N-Tyr
c-Brd
/BrdCrCrl; Charles River) 





mice were bred to B6.Cg-Tg(ACTFLPe)9205Dym/J (stock number: 




) mice.  To knockout 
Abcc6 in a cell-type and/or tissue-specific matter, these mice were bred to the following 
Cre expressing mouse lines, which were obtained from The Jackson Laboratory unless 
otherwise indicated: B6.C-Tg(CMV-cre)1Cgn/J (stock number: 006054; termed CMV-
Cre), B6.Cg-Tg(Alb-cre)21Mgn/J (stock number: 003574; termed Alb-Cre), B6.Cg-
Tg(Tagln-cre)1Her/J (stock number: 017491; termed SM22α-Cre), B6.FVB-Tg(Cdh5-
cre)7Mlia/J (stock number: 006137; termed VE-Cadherin-Cre), Pax7
tm1(cre)Mrc
/J (stock 
number: 010530; termed Pax7-Cre), B6.Cg-Tg(Cdh16-cre)91Igr/J (stock number: 
012237; termed Cdh16-Cre), Tg(Pdgfrb-Cre)
35Vli
 (a generous donation from Volkhard 
Lindner at Maine Medical Center; termed Pdgfrβ-Cre), B6.Cg-Tg(Fabp4-cre)1Rev/J 
(stock number: 005069; termed Fabp4-Cre), Ptprc
tm1(cre)Medv
 (a generous donation from 
Joseph Mee at the University of Edinburgh; termed CD45-Cre), 129S4.Cg-Tg(Wnt1-
cre)2Sor/J (stock number: 022137; termed Wnt1-Cre), and Tg(Cdx1-cre)23Kem (a 
generous donation from Jeremy Nathans at Johns Hopkins University School of 
Medicine; termed Cdx1-Cre).  The B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J 
(stock number: 007676, termed Rosa
mTmG
) mouse line was employed to mark recombined 
cells. 
 
For all crosses, litter size was normal, gender distribution of the progeny was balanced, 
and pups appeared healthy with the expected Mendelian patterns of gene transmission.  
Littermates were used as controls for analysis.  All mice were maintained on a C57BL/6J 
background; mice derived from other strains or substrains were backcrossed onto 
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C57BL/6J for at least five generations before proceeding with experimental crosses.  
Mice derived from other strains were also checked for the SNP at position rs32756904 in 
exon 14 of Abcc6 which has previously been shown to confound results when studying 
PXE in mice
316
.  All mice carried the non-disease associated allele in the homozygous 
state (G/G).  Sequencing methods described below. 
 
Mice were housed in a clean, specific pathogen-free facility with ventilated racks 
supplied with HEPA filtered, tempered, and humidified air and exhausted direct to the 
outside through the interstitial space above.  Mice were given ad libitum access to 
standard global 19% protein extruded rodent diet (Envigo) unless otherwise indicated; 
see Drug treatments section below.  Cages were supplied with reverse osmosis filtered 
hyperchlorinated water via an in-cage automatic watering system.  Light was controlled 
by central timer providing 14 hours light/10 hours dark.  The welfare of the mice was 
monitored daily by trained staff.  All animal experiments were approved by the Johns 
Hopkins Animal Care and Use Committee and performed with strict adherence to their 
guidelines (protocol number MO15M88). 
 
Mutation analysis 
For human subjects, genomic DNA was isolated from leukocytes.  For mice, genomic 
DNA was isolated from a piece of tail.  All exon and intron-exon boundaries of ABCC6, 
ENPP1, or NT5E were amplified by polymerase chain reaction (PCR) using genomic 
DNA as a template.  PCR was performed in a final volume of 10 µl containing 50 ng of 
genomic DNA, 1 µM of forward and reserve primers, and 5 µl of HotStart Master Mix 
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(Qiagen).  The PCR products were purified using ExoSap-IT for 45 minutes at 37 °C and 
sequenced in both directions using the same primers and the Big Dye terminator kit v3.1 
(Applied Biosystems).  Reactions were purified over G-50 Sephadex beads (Sigma-
Aldrich).  Linear amplification products were separated in an automated capillary 
sequencer (ABI PRISM 3130xl Genetic Analyzer, Applied Biosystems).  Sequences were 
analyzed with Sequencher software 4.8.  Primer sequences available upon request. 
 
Mouse genotyping 
DNA was extracted from a piece of tail using an NaOH extraction
317
.  PCR was 
performed in a final volume of 20 µl containing 2 µl of genomic DNA, 1 µM of each 
primer, and 10µl of REDTaq ReadyMix PCR Reaction Mix (Sigma-Aldrich).  PCR 
products were then run on a 1.5% ethidium bromide-containing agarose gel and 
visualized under UV light.  Primer sequences available upon request. 
 
Cell culture 
Primary dermal fibroblasts were cultured from a 3 or 4 mm forearm punch-biopsy 
specimen of skin, obtained from each patient, and grown in Dulbecco’s modified Eagle’s 
medium (Gibco) containing 10% fetal bovine serum (Sigma-Aldrich, Lot 15C177), 1 mM 
L-glutamine (Life Technologies), and 1% penicillin-streptomycin (Gibco), as previously 





A modified protocol for in vitro calcification was used for fibroblasts.  Cells were grown 
until confluent and were treated with 0.1 µM dexamethasone (Sigma-Aldrich), 50 µM 
ascorbic acid-2-phosphate (Sigma-Aldrich), and 10 mM β-glycerophosphate (Sigma-
Aldrich) in α-Minimal Essential Medium (Corning; termed αMEM) supplemented with 
10% fetal bovine serum (Sigma-Aldrich, Lot 15C177) and 1% penicillin-streptomycin 
(termed osteogenic media) for 21 days, with replenishment of the medium every four or 
five days.  On day 21, cells were washed with phosphate-buffered saline (Gibco) and 
fixed in 10% formalin (Fisher Scientific) for 10 minutes.  After washing with water, a 
solution of 2% alizarin red S (Sigma-Aldrich), pH 4.2, was used to stain calcium 
phosphate crystals.  Bright field images of cells were obtained using a Nikon 80i with a 
color camera and a 10x objective and the NIS Elements software (Nikon).  After imaging, 
to semi-quantify the staining, cells were incubated with 10% warm acetic acid for 30 
minutes at room temperature.  Cells were then scrapped down and spun at 16,000 g for 15 
minutes.  Supernatant was quantified at 405 nm on a spectrophotometer.   
 
ENPP1, TNAP, and CD73 enzyme assays 
Cells were seeded in 6-well plates and grown until confluent for five days.  To measure 
ENPP1 enzyme activity, cells were lysed in 100 mM Tris-HCl (pH 9.0), 500 mM NaCl, 5 
mM MgCl2, and 0.05% Triton X-100 and scraped into microcentrifuge tubes and kept on 
ice.  Cell suspensions were spun at 12,000 g for 5 minutes.  A 50 µl aliquot of the 
supernatant was added to a clear-bottom 96-well plate and the reaction with initiated 





For TNAP enzyme activity assays, cells were first stimulated with osteogenic media for 
five days.  Measurement of TNAP was performed with the use of the StemTAG Alkaline 
Phosphatase Activity Assay kit (Cell BioLabs).  Briefly, cells were washed with 
phosphate-buffered saline (Gibco) and then lysed and scraped down in Cell Lysis Buffer 
(Cell BioLabs).  Cell suspensions were spun at 12,000 g for 5 minutes.  A 50 µl aliquot of 
supernatant was added to a clear-bottom 96-well plate and the reaction was initiated by 
adding 50 µl of StemTAG AP Activity Assay Substrate (Cell BioLabs). 
 
Both ENPP1 and TNAP assays relied on the production of p-nitrophenol (pNP) to 
quantify enzymatic activity, as determined by absorption at 405 nm, and normalized to 
micrograms of protein (as quantified by a bicinchoninic acid assay; Pierce) over time 
(measured in minutes). 
 
To measure CD73 enzyme activity, cells were washed with 2 mM magnesium chloride, 
120 mM sodium chloride, 5 mM potassium chloride, 10 mM glucose, and 20 mM 
HEPES.  Incubation buffer, consisting of the wash solution supplemented with 2 mM 
AMP, was added, and cells were incubated at 37 °C for 10 min.  An aliquot of the 
supernatant was removed and inorganic phosphate was measured with the SensoLyte MG 
Phosphate Assay Kit (AnaSpec) according to the manufacturer’s instructions.  Inorganic 
phosphate measurements were normalized to micrograms of protein (as quantified by a 





RNA was isolated from cultured fibroblasts or solid organs with Trizol (Life 
Technologies) and the RNeasy kit (Qiagen).  Solid organs were first homogenized with 
the MP shaker.  RNA concentration and purity were measured on a Nanodrop ND-1000.  
First strand cDNA was synthesized using the high capacity RNA-to-cDNA kit (Life 
Technologies).  Quantitative PCR was performed utilizing 1 µg cDNA, TaqMan gene 
expression master mix reagents, and probes specific for human ENPP1, NT5E, ALPL, 
and ACTB and mouse Abcc6 and Gapdh (Life Technologies) on a QuantStudio 7 (Life 
Technologies) using the 2
-ΔΔCT 
method for relative gene expression. 
 
Histology and immunofluorescence  
Adult mice were humanely sacrificed via inhalation overdose of 2-Bromo-2-chloro-1,1,1-
trifluoroethane (Sigma-Aldrich).  Mice underwent immediate laparotomy, inferior vena 
cava transection, and phosphate-buffered saline was infused through the left ventricle to 
flush out the blood.  Organs of interest were then excised.  Organs were fixed in 4% PFA 
overnight at 4 °C before being subjected to dehydration with sequentially increasing 
concentrations of sucrose (10%, 20%, and 30% sucrose in phosphate-buffered saline) for 
12 hours at 4 °C.  Organs were then immersed in optimal cutting temperature compound 
(VWR Scientific) and slowly frozen over a liquid nitrogen bath.  Ten µm sections were 
cut on a cryostat and placed on SuperFrost slides.   
 
To visualize the location of calcification in the fibrous capsule of the vibrissae, 10 µm 
muzzle sections were stained with 2% alizarin red S (Sigma-Aldrich).  Histological slides 
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were then dehydrated in acetone and cleared in xylene before mounting with a synthetic 
mounting medium and imaged on a Nikon 80i with a color camera and a 10x objective 
with NIS Elements software (Nikon).   
 
Immunofluorescent slides were washed with phosphate-buffered saline before being 
sealed with Hardset VectaShield containing DAPI (H-1500) and imaged on a Zeiss LSM 
780 confocal microscope.  To test for tissue and cell specificity of Cre-mediated 
recombination, all Cre mouse lines were bred to a Rosa
mTmG
 reporter; expression of 
membrane green florescent protein indicates recombination.  Endogenous expression of 
tdTomato and green florescent protein were imaged.  To quantify the extent of mosaic 
recombination in the liver, the number of green hepatocytes was counted in three separate 
fields of view across three different Rosa
mTmG
;Wnt1-Cre adult mice. 
 
Drug treatments 
The development and characterization of the uncompetitive TNAP-specific inhibitor 
compound SBI-425 (PCT WO 2013126608; Preparation of pyridinylsulfonamide 
derivatives for use as TNAP inhibitors) was published previously
160,318
.  SBI-425 only 
binds to the enzyme in the presence of the substrate to form a three-way complex 
(inhibitor-enzyme-substrate) that effectively inhibits the enzyme.  The inhibition is 
reversible upon dilution of the complex.  Unlike bisphosphonates, SBI-425 does not bind 
to mineral where it could concentrate and provoke crystal toxicity.  For the in vitro 
experiments, 10 µM SBI-425 (dissolved in 100% DMSO) or DMSO-control was added 
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to the culture every time the medium was changed during the duration of the 21 day 
experiment. 
 
Mouse chow was formulated with SBI-425 (30 mg/kg/day) or etidronate (240 mg/kg/day; 
TCI America), assuming a 20 g mouse who consumes 2 to 5 g of food/day.  For SBI-425, 
the drug was crushed with mortar and pestle and added to powdered feed and vigorously 
mixed (300 mg of SBI-425 in 1 kg of powdered feed; LabDiet).  For etidronate, custom-
dyed food pellets were made after incorporation of etidronate into the feed (960 mg of 
etidronate in 1 kg of feed; LabDiet).  Control diet had the same standard base formulation 
as the drug-supplemented diets (LabDiet 5001). 
 
Micro-CT imaging and analysis 
All mice were imaged on a SPECT/CT (Gamma Medica X-SPECT) small animal 
machine.  For the Abcc6 and Enpp1 genetic crosses, mice were analyzed at 15 weeks of 
age; for the Abcc6 and Nt5e genetic crosses, mice were analyzed at 15 weeks and one 
year.  For the Abcc6
flox/flox
 mouse crosses, mice were analyzed at 20 weeks of age and one 
year.  For the treatment trial, mice were scanned at six weeks of age (baseline analysis 
before initiation of treatment) and at 20 weeks of age (final analysis after 14 weeks on 
treatment). 
 
Mice were anesthetized with continuous isoflurane during the acquisition of the micro-
CT scans.  Images were reconstructed and analyzed with ImageJ (NIH).  Briefly, a Z-
stack was created to encompass the entire region of pathological calcification (rostrally, 
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from the tip of the nose to caudally, the zygomatic arch).  To quantify this calcification, a 
threshold was manually determined to calculate the total area of ectopic calcification, 
excluding the radiodense nasal bones and sinuses.  For the treatment trial, data are an 
average of micro-CT analysis by six masked observers.   
 
Mouse plasma PPi assay 
Adult mice were humanely sacrificed with inhalation overdose of 2-Bromo-2-chloro-
1,1,1-trifluoroethane (Sigma-Aldrich).  Mice underwent immediate laparotomy and blood 
was obtained from the inferior vena cava and collected directly into EDTA-coated 
microcontainers (BD).  Samples were placed on ice and spun at 20,000 g for 5 minutes at 
4 °C within 5 minutes after sample collection.  Plasma was placed onto a centrifugal filter 
(Ultrafree-MC UFC30VV00, Millipore) and spun again at 20,000 g for 5 minutes at 4 °C.  
Filtrate was collected and stored at -80 °C until further processing.   
 
Detection of PPi relied on an enzymatic method to detect an ATP sulfurylase-catalyzed 
reaction and was modified from a previously published method
252
.  Briefly, 10 µl of 
plasma sample or known PPi standard (ranging from 0.05 µM to 10 µM; Sigma-Aldrich) 
was added to 40 µl of assay mixture containing 20 µM adenosine 5’ phosphosulfate 
sodium salt (Sigma-Aldrich), 25 µM MgCl2, 12.5 mM HEPES with or without 1 U/ml 
ATP sulfurylase (New England BioLabs).  The mixture was incubated at 37 °C for 30 
minutes and heat-inactivated at 90 °C for 10 minutes.  After centrifugation at 20,000 g for 
5 minutes at 4 °C, 10 µl of supernatant was transferred in duplicate to a 96-well white-
bottom plate.  One-hundred µl of CellTiter-Glo 2.0 (diluted 1:5, Promega) was added to 
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every well.  Luminescence was measured after a 10-minute room temperature incubation 
in the dark.  To generate a calibration curve, the luminescent signals were calculated by 
subtracting the blank signals (reaction without ATP sulfurylase) from the assay signals 
(reaction with ATP sulfurylase); the subtracted values were plotted against the PPi 
standards by a weighed least-squares linear regression method.  Samples with noticeable 
hemolysis were excluded from analysis because of red blood cell contamination. 
 
Calcium phosphate quantification 
Adult mice were humanely sacrificed with inhalation overdose of 2-Bromo-2-chloro-
1,1,1-trifluoroethane (Sigma-Aldrich).  Mice underwent immediate laparotomy, inferior 
vena cava transection, and phosphate-buffered saline was infused through the left 
ventricle to flush out the blood.  The muzzle was dissected from the underlying nasal 
bones and bisected.  Half of the muzzle was fixed in 10% formalin (Fisher Scientific) and 
frozen at -80 °C.  The muzzle was then freeze-dried with a lyophilizer and weighed.  The 
tissue was physically macerated before homogenizing with a bead homogenizer (MP) for 
15 minutes at 4 °C.  Tissue was then soaked overnight in 10% formic acid (Sigma-
Aldrich).  Samples were spun at 16,000 g for 5 minutes before 10 µl of the supernatant 
was used in a Calcium Quantification Assay (BioVision), as per manufacturer’s 
instructions.  Absorbance readings at 575 nm were normalized to tissue weight in grams. 
 
Mouse plasma alkaline phosphatase analysis 
At the conclusion of the treatment trial, mice were euthanized with inhalation overdose of 
2-Bromo-2-chloro-1,1,1-trifluoroethane before collecting blood by cardiac puncture with 
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a 21 gauge needle.  Blood was collected in lithium-heparin-coated microcontainers (BD) 
for alkaline phosphatase analysis.  Blood was spun at 150 g for 15 minutes at 4 °C and 
supernatant was collected and stored at -80 °C until assays were performed.  Residual 
alkaline phosphatase levels were assayed as previously described
319
.  Briefly, plasma 
samples were thawed on ice and spun at 2,400 g for 10 minutes.  The plasma samples 
were mixed with substrates in buffer in 3:1 volume ratio to initiate the reaction in a 1536-
well clear-bottom assay plate, with 1 mM MgCl2, 50 µM ZnCl2, 1 mM pNPP, and 100 
mM diethanolamine buffer at pH 9.8.  Ten µM of SBI-425 was spiked in control 
treatment plasma samples to determine non-TNAP phosphatase activity levels.  Samples 
were read kinetically for an hour on the PHERAstar FS plate reader at 380 nm, to detect 
amount of pNP produced. 
  
Bone microarchitecture and integrity studies  
At the same time of sacrifice, the femur and tibia were dissected out en bloc and muscles 
and tendons were carefully removed.  The bones were fixed in 4% PFA or stored at -20 
°C until ex vivo analyses were performed.  High resolution images of the mouse femur 
were acquired using a desktop micro-tomographic imaging system (Skyscan 1172, 
Bruker) in accordance with the recommendations of the American Society for Bone and 
Mineral Research (ASBMR)
320
.  Bones were scanned at 65 keV and 200 mA using a 0.5 
mm aluminum filter with an isotropic voxel size of 10 µm.  In the femur, trabecular bone 
parameters were assessed in the 500 µm proximal to the growth plate and extending for 2 
mm (200 CT slices).  Cortical bone structure was assessed 5 mm proximal to the growth 
plate and extending for 500 µm.  Following this, fixed bones were embedded in resin and 
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cut with on a macrotome; slides were stained with trichrome solutions.  Images of slides 
were captured on a Nikon 80i with a color camera and a 40x objection using NIS 
Elements software (Nikon).  Frozen femora were subjected to three point bending on a 




All statistical analyses and graphs were generated in R Studio.  One-way, two-way, or 
three-way analyses of variance with a Tukey’s honest significance difference post-hoc 
analysis were used to assess for major effects and determine if there were differences 
between multiple groups.  A one-tailed Student’s t-test was used to analyze between two 
groups.  All significant pairwise comparisons are shown and P-values indicated in the 
figures.  No outliers were excluded.  An alpha ≤ 0.05 was considered statistically 
significant.  Data obtained from the intercrossing of Enpp1-, Nt5e-, and Abcc6-deficient 
mice
 
were log-transformed before analysis to normalize the data.  For all graphs, the 




 centiles, respectively; the 
internal line defines the median, and the whiskers define the range.  Values outside 1.5 
times the interquartile distance are shown as open circles whereas values outside 2 times 
the interquartile distance are shown as filled circles.  Number of biological replicates in 
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